Welcome to Global Perspectives #4 2024
Dear HAEi Friends,
Welcome to this fourth and final edition of Global Perspectives for this year. With 2024 drawing to a close, we reflect on a highly successful year powered by the motivation, energy, and enthusiasm of our HAEi global advocacy community.
Our numbers continued to grow, and we welcomed member countries 100 and 101 to the HAEi family in HAE Zimbabwe and HAE Nepal. Both are led by determined and driven advocates already making significant progress in their countries. We finish 2024 with an RPA team of 12 proven advocacy leaders, our “on-the-ground forces” implementing HAEi’s programs, activities, and services worldwide.
Our tools and expertise are always ready and available to support these new organizations as they are for every single Member Organization (MO). In addition, we continue fulfilling our commitment to developing new and vital resources. In 2024, we launched HAEi FocalPoint as a ‘one-stop’ tool for all MOs to interact with HAEi, a Travel and Relocation guide, and updates to our essential HAEi Connect and HAE TrackR resources.
While 2024 brought many positive achievements, it was also marked by profound loss. We were deeply saddened by the tragic passing of our Chief Medical Advisor, Professor Marcus Maurer, in late July. Marcus was more than a brilliant mind—he was an inspirational leader, a steadfast ally, and a dear friend to the global HAE community. The loss of Marcus is beyond words, and he will be sorely missed. We dedicate ourselves to continuing his legacy.
A fundamental part of Marcus’ legacy is HAEi’s partnership with GA2LEN on the Angioedema Centers of Reference and Excellence (ACARE). In 2024, the partnership delivered the first ACARE Global Angioedema Forum 2024, affectionately known as the GAF. For physicians and scientists, the GAF was a two-day celebration of the science behind angioedema and its treatment, focusing on HAE. The success of the meeting is a tribute to Marcus.
In-person meetings remain the lifeblood of HAEi’s efforts to share the state-of-the-art in HAE advocacy, and we saw two fantastic patient-led meetings in 2024: the HAEi Regional Conference Americas and the HAEi Global Leadership Workshop. Across both meetings and the GAF, we welcomed 1,400 participants, representing many patients, caregivers, advocacy leaders, healthcare professionals, and pharmaceutical representatives currently active in HAE.
On behalf of the Board, the HAEi Leadership Team would like to thank everyone who has helped make 2024 such a great success. Together, we have made considerable progress; however, we know our work will only be done when there is approval and reimbursement of lifesaving therapies for everyone suffering from HAE. Looking ahead, 2025 promises to be a year of continued vigorous support for MOs as they work to improve the lives of people with HAE in their respective countries. We are excited about the upcoming 2025 HAEi Regional Conference Asia-Pacific (APAC) in Manila, Philippines, in March and are working hard towards a second conference for Europe, Middle East, and Africa (EMEA) in the fall of 2025. Stay tuned for more news! Our regional gatherings provide exceptional opportunities for connecting with HAEi friends and sharpening the advocacy skills that lead to breakthroughs in access to HAE therapies.
Warm regards and Happy Holidays.
Anthony J. Castaldo
Chief Executive Officer and Chairman of the Board, HAE International (HAEi)Henrik Balle Boysen
President, HAE International (HAEi)
News from HAEi’s Regional Patient Advocates
HAEi Regional Patient Advocates – Continuing to Advance HAE Advocacy!
Time seems to pass in the blink of an eye, and it’s hard to believe that we are at the end of another impactful year of advocacy.
This provides the perfect opportunity to reflect on the past twelve months and the work of HAEi’s Regional Patient Advocates (RPA) and how their support has an incredibly positive impact on HAEi Member Organizations (MO), patients, and their families.
2024 has been quite a year! In the following articles the RPAs will share highlights from the year and their hopes for 2025.
As a Director of the RPA Program, I am delighted to share key achievements, many of which have been shared through our social media platforms, website, and this magazine:
- A total of 101 HAEi Member Countries, with the addition of HAE Nepal and HAE Zimbabwe
- Of the 101 Member Countries, 73 now have access to at least one modern on-demand treatment option, while 54 have access to at least one modern long-term prophylaxis medication. However, availability varies by country and often depends on complex and time-consuming procedures.
- The HAEi RPA Team has grown to 12 members.
- HAEi research, “The State of Management of HAE,” has been completed across 28 countries in Europe (including both EU and non-EU states) and in 15 countries across the Middle East and North Africa.
We have achieved a lot in 2024. Do we have more to do? Absolutely! That is why the RPAs stay focused on one of HAEi’s top priorities: Advancing HAE advocacy and improving the lives of those affected by this debilitating condition.
Stay tuned!
Michal Rutkowski
Director, Regional Patient Advocate Program
News from Sub Sahara Africa
From Regional Patient Advocate Patricia Karani
2024 Highlights
It has been an exciting year for Africa as we finally had new Member Organizations (MO) joining HAEi, thanks to patient leads taking up the role in the individual countries. We have worked extensively with HAE Mozambique, HAE Comoros, and HAE Zimbabwe to find support from local doctors interested in raising HAE awareness and supporting HAE patients in their countries. This has involved a lot of dialogue, HAE training, and HAE talks and seminars. We are glad to have found doctors willing to collaborate with the local MOs and raise more awareness in their countries.
We are also excited to be part of the new genetic testing program being rolled out in some African countries, as this will help us identify more HAE patients and get doctors knowledgeable about HAE in the region.
The 2024 HAEi Global Leadership Workshop was a great opportunity for HAE group leads and doctors to learn and interact. The GLW and Global Angioedema Forum 2024 highlighted that HAE is a family, and we all collaborate as individual stakeholders to realize our goals: early diagnosis, correct treatment, and proper management of HAE.
Hopes for 2025
I am excited about the new prospects for HAE awareness in our region. Plans are already underway in the MOs to have more awareness activities and ideas that will create impact and enlighten more people on the burden of illness and the need for more interventions regarding early diagnosis, treatment, and management of HAE in Africa.
News from South Eastern Europe
From Regional Patient Advocate Natasa Angjeleska
2024 Highlights
The South Eastern Europe (SEE) HAEi meeting: PROVIDING BETTER CARE FOR HAE FAMILIES held in Skopje, North Macedonia, 31 May – 1 June gathered representatives (patients, caregivers, and physicians) from 9 countries: Albania, Croatia, Greece, Kosovo, Montenegro, North Macedonia, Slovenia, Serbia and Turkey. It was a remarkable opportunity to see the progress each country has made from the very first SEE gathering back in 2016 in terms of HAE awareness and advocacy activities, reaching out to more HAE patients, having more physicians interested in HAE, as well as increased use of HAEi resources.
For the State of Management of HAE study in SEE, data collected from Member Organization (MO) leads in June 2024 were analyzed and presented to more than 70 participants during the 2024 HAEi Global Leadership Workshop (GLW) and at a high-level meeting with officials in Albania. The GLW provided an opportunity to converse and discuss the different opportunities where the data can be used for advocacy, especially because it offers comparable data between countries in different areas: diagnosis, treatment, care, quality of life, and access to medicines.
I was delighted to see increased interest from MOs in translating the resourceful booklets ‘Understanding HAE’ and ‘Women with HAE’ in local languages and using different HAEi resources: HAE TrackR, HAEi Connect, and FocalPoint.
Hopes for 2025
- To help MO leads and members keep up the inspiration and energy to stay active and navigate the future for improved quality of life for all people with HAE and their family members.
- To assist more countries with access to preventive therapy according to individual needs.
- To facilitate and build a stronger and more vibrant HAE patient and caregiver community, advocating for improved quality of life in SEE.
- To support at least one more patient organization officially registered in the region – in Kosovo.
- To support different hospitals/clinics in becoming members of the ACARE network.
- To gather at the second HAEi Regional Conference EMEA in 2025.
News from South Asia, Germany, Austria, Switzerland, and Israel
From Regional Patient Advocate Fanny Schappler
2024 Highlights
I’m excited to have joined HAEi for the last quarter of 2024 and have witnessed tremendous growth in South Asia in the last few months;
- The Nepalese HAE patient group was officially created in October 2024
- The Indian patient group held its first in-person patient and caregiver meeting in Hyderabad in November 2024, after managing successfully to secure a grant from a pharmaceutical sponsor
- Bangladesh held an online educational webinar for doctors with over 30 attendees.
The DACH countries were also actively preparing their annual assembly meeting or modernizing their websites. This is a testimony of the hard work of each of the Member Organization (MO) leaders, connecting the dots, advocating for their community, and ensuring this is done in partnership with physicians to maximize impact.
Hopes for 2025
In 2025, I hope to see the Sri Lankan HAE patient group formally coming together. In addition, I hope to see more patients joining our MOs in each country and to see the impact of their unity when they act as one group in each country to advocate for the needs of their community. As this infamous African proverb says: “If you want to go fast, go alone. If you want to go far, go together.”
News from South America and Mexico
From Regional Patient Advocate Fernanda De Oliveira Martins
2024 Highlights
2024 was a pivotal year for the HAE community in South America and Mexico. Our region’s robust participation in both the 2024 Regional Conference Americas and the 2024 HAEi Global Leadership Workshop underscored the value of these gatherings in fostering connections, knowledge sharing, and inspiration among Member Organization (MO) members. A significant milestone was the inclusion of representatives from Bolivia, expanding our collaborative network. To bolster HAE expertise within our region, we actively supported a training program led by Spanish physicians. This initiative aims to equip more healthcare professionals with the necessary knowledge and skills to provide optimal care for HAE patients.
Furthermore, we actively engaged in public consultations on access to modern therapies in Brazil. By advocating for increased access, we strive to ensure that more individuals with HAE can benefit from life-changing treatments.Hopes for 2025
I hope 2025 will be a year of significant progress for the HAE community in South America and Mexico. I aim to strengthen regional collaboration by continuing to foster strong connections among MOs HAE advocacy organizations, caregivers, healthcare professionals, and pharmaceutical companies; and to expand access to care through advocating for equitable access to modern HAE therapies in the region.
News from Oceania and South Africa
From Regional Patient Advocate Fiona Wardmann
2024 Highlights
I’m an RPA for countries in the APAC region and South Africa, and seeing the growth within individual Member Organizations (MO) has been remarkable. They support more patients than ever to learn about HAE, access clinical trials, and access modern medications.
Another highlight was seeing so many MO leaders from the region participate in the 2024 HAEi Global Leadership Workshop and take so much back home to implement in their countries.
I had the opportunity to attend in-person and online patient meetings and scientific conferences in China, Nepal, Bangladesh, Korea, Singapore, India, and Australasia. I also attended the 2024 patient meeting in South Africa. It was a privilege to witness their progress firsthand and to see the increasing knowledge and interest in HAE in these countries.
We end the year with five RPAs covering the APAC region. We collaborate closely to share successes, challenges, and information to support each other and enhance our work.
Hopes for 2025
My hopes for the countries I support include creating more clinical trial opportunities for patients without access to modern therapies so that they can live as normal a life as possible.
I aim to work closely with MOs to strengthen their organizations, secure funding, and expand awareness and education about HAE to better support patients and their families.
I’m excited to connect with more patients and families at the 2025 HAEi Regional Conference APAC in Manila, engage with the South African community during the 2025 HAEi Regional Conference EMEA, and help make both conferences a huge success.
News from Nordics
From Regional Patient Advocate Jørn Schultz-Boysen
2024 Highlights
The 2024 HAEi Global Leadership Workshop and ACARE Global Angioedema Forum 2024 brought together leadership from Member Organizations (MO), healthcare professionals, and physicians, including participants from my region countries of Finland, Sweden, Norway, and Denmark. The event offered opportunities to explore the latest advancements in angioedema care, learn about advocacy tools and resources, and strengthen efforts within their countries. It also (re-)created connections among attendees, highlighting the power and impact of a united, collaborative community.
Meeting patients locally in Finland and Denmark through MOs was another key highlight. These gatherings provided a platform for participants to share experiences, gain insights into new treatment options, and explore HAEi resources. Such meetings emphasized the value of local engagement and strengthened both advocacy efforts and a sense of community, bringing people together around shared challenges and goals.
An exciting milestone this year was the launch of SumsUp, a digital tool created by HAE Scandinavia and an HAEi LEAP 23 student. Initially designed for youth, SumsUp has proven useful for all age groups. The app offers HAE advice and reassures users they are not alone. Currently, SumsUp is being upgraded into a native iOS and Android app, increasing its accessibility and impact across Scandinavia.
Hopes for 2025
In 2025, my goal as an RPA is to improve the quality of life for individuals with HAE and their families while ensuring continued access to modern treatments. I am eager to witness the advocacy and empathy of HAE communities and look forward to hae day :-), a key opportunity to raise awareness. Another highlight will be the Regional Conferences uniting patients, caregivers, healthcare professionals, and pharma representatives. Additionally, the LEAP25 program will welcome a new cohort of young advocates, including Students from my region. For the Nordics, I aspire to connect with more patients and caregivers, especially in underserved areas.
News from Mediterranean, North Africa, Benelux and British Isles
From Regional Patient Advocate Maria Ferron
2024 Highlights
2024 has been a remarkable year for the global HAE community. In my region, we saw many significant events and developments underscoring our collective commitment to raising awareness and fostering patient support. Highlights include:
- In March, the inaugural face-to-face ADAH (HAE Portugal) meeting was held in Lisbon. During this event, I was privileged to introduce HAEi’s comprehensive services, tools, and resources to attendees, enhancing understanding of HAE and its management.
- In Barcelona, the 9th CSL HAExpert Face-to-Face Meeting (for healthcare professionals) served as another vital platform for raising awareness about HAE and the valuable initiatives HAEi undertakes.
- We witnessed the appointment of a new patient advocate in Belgium, who is actively working to register a national HAE association, fostering community support (the Dutch association has been- and is- a great support) and resources for local patients.
- In Ireland, our new patient lead has been engaging in various activities to raise awareness and advocate for HAE patients, reinforcing the critical need for ongoing support and education in the country.
I’m delighted to see the progress in my region’s countries, ensuring a brighter future for patients worldwide.
Hopes for 2025
- Try to establish a patient group in Mauritania.
- Organise the first HAE meeting in Tunisia.
- Keep helping Member Organizations implement the tools and resources that we offer to run their associations/patient groups smoothly.
- And keep working to help provide access to HAE modern treatments to as many patients as possible.
News from East Asia
From Regional Patient Advocate Lim Yong Hao
2024 Highlights
My region has seen significant progress in raising awareness and advancing research on HAE. A key highlight is the considerable media coverage across platforms like online news, YouTube, and social media, with at least 40 features promoting HAE awareness. Notably, the Illness Challenge Foundation in China engaged celebrities to share videos on Douyin, and 22 Japanese landmarks were illuminated in purple to mark hae day :-) supported by the Discovery Consortium.
Scientific research on HAE has also grown substantially. Publications from the region increased from 15 annually in 2021 and 2022 to 28 by November 2024. These works, including systematic reviews, clinical trials, and case reports, reflect a rising interest in HAE research. Regional Medical Advisory Panels (RMAPs) and other physicians are actively collaborating to enhance understanding of HAE diagnosis and treatment in the region, with another impactful manuscript currently pending publication.
Lastly, the breakout session at the 2024 HAEi Global Leadership Workshop brought together patient leaders from Member Organizations (MO) to share experiences and strategize regional collaboration. This rare gathering promises to foster partnerships and more learning opportunities, hopefully strengthening efforts to improve the lives of HAE patients across the region.
Hopes for 2025
My hope for 2025 is to see greater collaboration among MOs within the region. Such partnerships have the potential to foster innovative ways to raise public awareness about HAE, leading to a more significant impact. I also hope for sustained scientific collaboration throughout 2025, advancing progress in research. The synergy between these public awareness and scientific efforts would enhance opportunities to expand access to clinical trials and treatments in more countries across the region.
News from Central Eastern Europe and Middle East
From Regional Patient Advocate Michal Rutkowski
2024 Highlights
Celebrating 20 years of milestones in HAE advocacy, a highlight from this year was the 2024 HAEi Global Leadership Workshop. The meeting played a crucial role in cementing advocacy as the key to maintaining the progress we’ve made; there is always a risk of losing momentum if we don’t actively safeguard hard-won gains for the future. To ensure continued success, it’s essential to have motivated Member Organizations (MO), dedicated patients and caregivers, expert physicians, and committed industry partners working together.
Strengthening advocacy in the Middle East through strategic collaboration with HAEi Member Organizations in the region has delivered many advances. It has been truly inspiring to witness the significant progress in awareness, patient numbers, access to treatments, and physician engagement in HAE care across the Middle East over 2024. Ongoing collaboration with MOs in the region, along with the implementation of key HAEi resources, has brought the HAE community together, highlighting shared challenges and diverse needs.
Two major youth events organized by HAEi MOs in Czechia and Poland were pivotal in engaging young people with HAE advocacy. As the future of the community, it’s essential that young people are fully informed about all aspects of HAE and become passionate, knowledgeable advocates. Their role will be to share HAE experience with future generations while ensuring continued access to and reimbursement for HAE treatments.
Hopes for 2025
- To foster greater creativity in collaboration with HAEi MOs, enabling them to implement effective advocacy resources that drive further success and improve the local situation for patients.
- To establish contact with patients in countries within my region who are not yet members of HAEi and to continue to support the growth of existing MOs. Also, more tools and resources should be implemented by HAEi.
- To support establishing 2 more HAEi MOs in my regions and several ACARE centers. Also, to help approve access to modern HAE treatment options in countries where discussions with health authorities are currently in progress.
News from Central America and Caribbean
From Regional Patient Advocate Javier Santana
2024 Highlights
The first HAEi Regional Conference Americas was held in Panama City, Panama (in my region), which motivated and inspired my region’s HAE groups towards achieving their goals in each country.
Specific highlights include:
- Post-conference, the newly elected Panama Government has been more open to addressing the needs of the HAE patient group.
- The Dominican Republic patient group became a government-registered entity. They can now work as a legally constituted group in their country.
- The authorities in Costa Rica approved another HAE therapy, allowing patients to have medication at home to treat their attacks. 2 modern HAE medications have been approved in Costa Rica in less than a year.
- The first HAE Law was finally approved in Puerto Rico. The Law mandates that Hereditary Angioedema is included within the Government’s Catastrophic Diseases Law, which means HAE must be included in Medical Schools, the recognition of HAE Day, that public and private health plans include treatments for HAE in their coverage, and that hospitals and emergency rooms have treatment guides available for HAE.
Additionally, the 2024 HAEi Global Leadership Workshop and the ACARE Global Angioedema Forum 2024 included great representation from countries in my region.
Hopes for 2025
I will continue to work hard and enthusiastically to support the patient groups in my region to ensure that more countries have access to treatments for HAE. In addition, we will use our resources to address issues in countries where doctors still do not recognize HAE as a disease, there are no modern treatments for HAE, and patients feel unprotected by medical representatives.
hae day :-) is Coming
Mark 16 May 2025 for hae day :-)
hae day :-) is our annual celebration of the HAE community and a key focus for awareness-raising efforts. Our activity challenge continues to record the steps you generate—solo or as part of a team—through your time spent on physical and wellbeing activities. As you prepare for hae day :-) 2025, our haeday.org website has lots of practical information to help you plan your media engagement, community involvement, or social media, as well as lots of inspiration for activities from our Member Organizations.
In 2024, the Mexican Association of Hereditary Angioedema (AMAEH) marked the first legally mandated National Hereditary Angioedema Day in Mexico with a program of events and activities that raised public awareness and provided a focus point for the HAE community. Global Perspectives brings you all the details to help inspire your activities for 2025.
hae day :-) 2024: AMAEH
The problem
In Mexico, with a population of more than 132 million people, it is estimated that there are 2,116 people with HAE. At the start of 2024, only 393 people were recorded as having HAE. This means that more than 80% of people with HAE in Mexico are undiagnosed or have died.
Sandra Nieto, the President of AMAEH, comments, “We give all our love and efforts to our family members, caregivers, friends, and those with HAE. We continue to fight because we will not allow one more death.”
In recent years, AMAEH has been highly successful in lobbying policymakers and elected lawmakers. Mexico became the first country to have a National Day of HAE legally declared at a legislative level. The organization wanted to acknowledge the first National Day and maximize its impact.
The objectives
- Address incorrect diagnosis and lack of access to appropriate HAE therapy, in the hope of preventing unnecessary deaths from the disease.
- Build greater empathy for people living with HAE and help others understand and recognize their strength.
- Recognize the patients, caregivers, family members, and all who support them.
- Raise awareness of HAE among the general population, including healthcare professionals.
- Share the journey for people with HAE, with the general public.
- Ultimately, place the patient at the center of attention. Advocate for people with HAE to receive the care they need from the healthcare system and society.
The activities
AMAEH Award 2024
For 2024, AMAEH gave three awards to members of the Mexican HAE community. The recipients were:
Luis Héctor Montañez Nieto
Luis Héctor saved his mother’s life for the first time 10 years ago. He guided paramedics as they gave life-saving medication to his mother following a severe HAE attack. Since then, he has been trained to administer intravenous and subcutaneous medications. He has also arranged training on HAE for children, adolescents, and adults, including how to give essential medicines for the disease.Karla Sofía González González
Sofí first learned to administer medicines at the age of 5, giving insulin to her grandfather and grandmother. At the same age, she began to give her mother the medicine she needed to manage her HAE. Just 1 year later, at the age of 6, Sofí received training at the National Institute of Pediatrics so she could give intravenous medications, which ultimately saved her mother’s life on multiple occasions. Alongside all this, Sofí has HAE herself, which she calmly manages with self-administration of medicines.Gabriela Sodi Miranda
Deputy Sodi is an elected politician in Mexico. She is President of a Commission on vulnerable groups in the Mexican Congress of the Union. Throughout her political life, he has championed the vulnerable and those facing discrimination. With this award, AMAEH acknowledges his efforts to bring about the National Hereditary Angioedema Day.Paths of HAE: Walking through history
To coincide with the HAEi activity challenge to support hae day :-), AMAEH conducted a walk. This took place in the historic and archaeologically significant site of Cuicuilco. This site was chosen as it is a popular visitor attraction. AMAEH placed signs along the walking routes to raise awareness. The site also boasts a pyramid, which, due to its unusual features, provided an excellent metaphor for the exceptional nature of HAE.
In May, the entire AMAEH team, including patients, relatives, and caregivers, walked more than two million steps, which were uploaded to the hae day :-) activity challenge website.
Symposium
A one-day conference was planned and delivered on the National Day of HAE in Mexico. The conference focused on the individuals behind the disease and looked at some ways in which HAE had been seen in ancient and indigenous civilizations. There were many speakers on a diverse range of topics, including:
- Deputy Gabriela Sodi Miranda spoke (via video link) to explain the thinking behind the declaration of a National HAE Day.
- Dr. Alberto Contreras Verduzco explained the basics of HAE, including how the disease occurs, who it affects, and why, as well as common aspects such as triggers, prodromes, tests, and available medications.
- Dr. Sandra Nieto Martinez, President of AMAEH, presented data from the HAEi Baseline Burden of Illness survey conducted in Mexico. The survey examined why people with HAE do not go to the emergency services during an attack and the impact that HAE disease has on every aspect of their lives.
- Dr. Ma. Eugenia Vargas Camaño, a specialist in allergy and clinical immunology and an art historian, spoke about how HAE was referred to in history and, similar to today, was confused with other conditions.
- Amanda Silvana Patiño Cruz spoke about the potential benefits of an anti-inflammatory diet in patients with HAE. Ms Patiño recommended that patients observe any reactions they may have to foods and avoid those they consider to generate an adverse reaction.
- Maricruz García Bárcenas, a Master’s student of cultural diversity and Indigenous social spaces, asked: Are Indigenous communities in Mexico free of rare diseases? Ms García showed that life expectancy improved following advances in access to healthcare for indigenous people. However, the current model of care did not serve these individuals and communities well, preventing the timely detection of rare diseases in this population.
- Dr. Jesús Navarro Torres, Vice President of the Ibero-American Alliance for Rare Diseases and President of the International Organization of Low Prevalence Diseases, discussed the many challenges faced by people with rare diseases. He felt that there is strength in numbers; by speaking together, it will be possible to address medical ignorance of these conditions.
Sensorama
Following the conference, AMAEH developed a sensory experience for attendees. This allowed participants to put themselves in the shoes of people living with HAE, helping build empathy.
The results
The symposia welcomed 114 in-person attendees and 1,300 virtual attendees on Facebook Live, who were drawn from Mexico, Argentina, Brazil, Panama, Bolivia, and Peru.
Media activity to support awareness-raising led to 9 pieces of media coverage, including in Mexican news media such as La Jornada, TV channel a+, and the online medical publication hematology.mx. This coverage was the equivalent of many thousands of dollars in advertising.
To support the National Day of HAE, a wide range of video and visual content was produced and shared on Facebook and X.
Inspired by AMEAH?
AMAEH used a wide range of ideas to maximize their impact around hae day :-)
- The hard work of securing a legal declaration of a national day can be replicated through political advocacy.
- Awards offer an opportunity to recognize the people who work tirelessly to support the HAE community and improve the lives of people with HAE.
- Looking at the broadest possible impact and aspects of HAE can interest more people; using ancient societies and history gives a new perspective on HAE.
- A creative approach can deliver benefits, but this can take time and require financial investments, which may only be possible for some Member Organizations.
AMAEH’s acknowledgments and thank yous
AMAEH offers special recognition to those who dedicated their lives to this and who went ahead of us on the path: Dr. Marco Cicardi (Italy), Dr. José Egidio Fabiani (Argentina), and Dr. Silvestre Frenk Freund (Mexico). AMAEH thanks everyone and all the organizations that contributed their time, energy, and support to make these activities successful.
HAEi: Leading Positive Change for 20 Years
HAEi is a global non-profit network of patient associations dedicated to improving the lives of people with HAE. 2024 was HAEi’s 20th year of raising awareness of HAE, fiercely advocating for those with HAE and supporting our Member Organizations to address the unique needs of people with HAE and their families. We highlight some of our developments and achievements over those two decades.
Towards Better Diagnosis and Care for HAE Patients in Europe
HAEi participates in European Parliament panel debate
HAE is the perfect example of why urgent, coordinated European Union (EU) action on rare diseases is long overdue. Despite a simple blood test, there are prolonged diagnostic journeys, inconsistent standards of care, and unequal access to treatment.
“HAE has the potential to become a beacon of hope for all rare diseases.”
–Henrik Balle Boysen
Addressing HAE Challenges Across Europe
HAEi was invited to a recent European Parliament panel debate, organized by CSL Behring, about improving HAE care. The discussion brought together policymakers, medical professionals, and patient advocates. Henrik Balle Boysen, President of HAE International (HAEi), emphasized that HAE is a manageable condition, but barriers like reimbursement delays and rigid eligibility criteria for prophylactic treatments remain.
“HAE patients must not have to prove multiple attacks before accessing life-saving medication.”
– Henrik Balle Boysen
Findings from HAEi’s own State of Management report across 25 EU Member Organizations revealed critical gaps in awareness and care within the EU:
- Only 4% of member organizations rated general physicians’ knowledge of HAE as ‘Good’ or ‘Very Good’
- Without medication, more than half of respondents stated that HAE highly limits education, work, and social opportunities.
- Despite the majority of countries allowing self-administration of modern treatments, access remains uneven.
Advancing Rare Disease Policies
The debate underscored the need for an EU Action Plan on Rare Diseases, which could enhance coordination among stakeholders, streamline treatment approvals, and foster innovation. Enrique Terol, Health Counsellor at Spain’s Permanent Representation to the EU, highlighted Spain’s leadership in supporting a potential World Health Assembly Resolution on Rare Diseases in 2025. This move could strengthen international efforts.
Advancements like the European Reference Networks (ERNs) and the Angioedema Centers of Reference and Excellence (ACARE) are improving access to experts. However, further integration into national health systems is crucial. Former European Commissioner Vytenis Andriukaitis (MEP) stressed that rare diseases must remain a priority, with systems designed to meet patient needs.
Speakers also discussed how initiatives like the EU Life Sciences Strategy and updates to pharmaceutical legislation can improve access to next-generation therapies for rare diseases. MEP Stine Bosse highlighted the broader implications of failing to diagnose and manage rare diseases effectively: “Patients should be at the center of the Life Sciences Strategy, and collaboration with industry and investors is essential for building a competitive and resilient Europe.”
Collaborative Efforts and Empowerment
Experts agree that multistakeholder collaboration is essential. Professor Mauro Cancian from the University of Padua pointed out the critical role of partnerships among patients, researchers, healthcare professionals, and industry in accelerating diagnosis, clinical trials, and equitable treatment access.
HAEi continues to advocate for professional education programs to help physicians recognize and treat HAE, empowering patients with tools like the HAE TrackR app and supporting individualized care plans based on quality of life rather than attack frequency.
By fostering collaboration among governments, regulators, and the rare disease community, Europe can ensure that advancements in HAE treatment translate into meaningful improvements in patient lives. Bold EU action, combined with national-level implementation, is critical to achieving a future where every person with HAE can live their life to its fullest potential.
The Birth of Advocacy in Nepal
In the whirlwind of just a few short weeks, HAE Nepal became HAEi member country #101. Its driving force is Ganesh Dahal. Global Perspectives caught up with him, and pioneering Nepalese immunologist Dr. Dharmagat Bhattarai, to hear more about the situation in the country, and what it takes to start advocacy from nothing.
Ganesh’s journey to forming HAE Nepal
Ganesh’s motivation stems from the knowledge that nobody should have to lose their life because they’re undiagnosed or lack treatment. This is personal too, with Ganesh having lost his father to undiagnosed HAE.
Ganesh’s own life with HAE began in 2010, when he experienced his first attack. In the years that followed there were other attacks, mostly abdominal but with occasional facial swellings. Ultimately, a facial swell led Ganesh to India where eventually he was diagnosed. Sadly, a diagnosis didn’t come in time for his father, but that tragic loss had a profound impact, igniting a passion in Ganesh to do something for the HAE community in Nepal.
Ganesh’s situation now is a microcosm of HAE in Nepal. The only treatments available are tranexamic acid, danazol, or fresh frozen plasma. Ganesh doesn’t medicate when he has episodes in his hands and legs. For swellings in his abdomen, face, or neck, he seeks medical help, but in the main, this is only a secondary treatment to reduce pain.
Stepping back to diagnosis, this is a pressing issue in Nepal. Ganesh is clear the main problem is doctors’ lack of awareness of HAE. Yet, there are already signs of improvement thanks to Ganesh and two committed clinicians, Dr. Dharmagat Bhattarai and Dr. Sudip ParajuliI. With HAE Nepal just starting, around 40 Nepalese doctors have been educated about HAE, including diagnosis, while a Facebook community has already attracted 20 members. A community that Ganesh believes will be more impactful together, telling us: “The ocean is made from small drops of water that flow through the rivers. They might not listen to one, but if you go in a group of 100, they will.”
If HAE Nepal seems to have hit the ground running, it’s largely due to Ganesh’s dynamism. After a successful career, he finally had the time to realize his dream of doing something for people with HAE, partly as a way of honoring his late father. After contacting the US HAEA, he found himself speaking to Fiona Wardman and Fanny Schappler, HAEi Regional Patient Advocates in Asia-Pacific. Both brought vast experience in HAE advocacy, which gave Ganesh further confidence to make HAE Nepal a reality.
But what is it that gave Ganesh the motivation right now? How would he encourage others to take that first step? He says that: “It should always come from your heart. Look at the impact that you are going to create and the value you can add to someone else’s life.” For Ganesh, there was a ‘spark within’ that told him to believe and begin telling the HAE story to doctors and government bodies. That single spark has set in motion the creation of the newest HAE advocacy organization in a matter of weeks, with huge promise in the coming months and years.
>> Visit HAE Nepal’s website to find out more about the organization
The only immunologist in Nepal
Nestled amongst the literally breathtaking Himalayas lies Nepal, home to over 30 million people and one immunologist. Dr. Dharmagat Bhattarai is that specialist, and he’s on a mission to improve the lives of people with HAE.
Dr. Bhattarai returned to Nepal in 2020 but found no specialist immunology professionals, few facilities for people living with HAE, such as testing for C1 and C4 inhibitor levels, and no effective medicines. Despite the seemingly overwhelming odds, Dr. Bhattarai has since established a center to diagnose immune deficiencies and HAE, in Kathmandu, the capital of Nepal.
In just four years, Dr. Bhattarai’s institute, Immunocare Nepal, has been able to take on some of the key tests necessary to diagnose HAE. Procedures such as genetic testing and the measurement of C1 inhibitor function are not yet available in Nepal; Dr. Bhattarai explained that patients in Nepal need to pay for these diagnostics tests to take place in India.
Dr. Bhattarai’s efforts mean that he has diagnosed 15 Nepalese patients from a standing start. Combined with a family of six who were diagnosed abroad, this means he is now aware of 21 confirmed cases of HAE in Nepal. According to Dr. Bhattarai, prevalence estimates indicate that there are likely to be hundreds of cases currently undiagnosed or misdiagnosed as allergies. He suspects HAE in around 34 cases but has only been able to confirm 15, often due to the absence of advanced testing. The stigma of the condition has also hampered diagnosis, with some family members being unwilling to be tested, even when others in the family have been diagnosed.
Despite advances in diagnosis, as Dr. Bhattarai told us, treatment is virtually non-existent. The only medicines are tranexamic acid or steroids, which, he says, are not very effective. Speaking directly about the problem facing people in resource-constrained countries, Dr. Bhattarai said, ‘Two patients have been able to buy medicines from another country and bring them home, but it’s impractical because it’s not every day you can go to another country and bring medicine home. It’s heartbreaking.’
Dr. Bhattarai is partnering with HAEi. Fiona Wardman, a Regional Patient Advocate for Nepal, traveled to the country to support patient advocacy efforts, including a successful patient gathering in Kathmandu. She has also worked with Dr. Bhattarai to advance the cause of HAE in meetings with Nepal’s Ministry of Health. Dr. Bhattarai said these meetings were impactful, “The officials were positive about the disease. We were joining hands to promise further progress. There are many difficulties and constraints as this is a resource-limited country. The focus is on common diseases, even malnutrition. But they gave a positive signal for commitment.”
Dr. Bhattarai believes all this is valuable progress. His work to date has also included many awareness-raising activities. He has been active on social media, has given interviews to television news and other media, and has lectured on HAE to Nepalese medical students. He has also formed two societies, one for patients with primary immune deficiencies, such as HAE, and the other for healthcare professionals: the Nepalese Immunology, Allergy and Pediatric Infectious Disease Society (NIAPIDS).
Dr. Bhattarai is keen to thank the many people who have helped him to date, including a Berlin clinic, which has provided invaluable support to some of his patients. He is also upbeat about the potential for diagnosing and treating HAE in Nepal. His message to anyone working in a resource-constrained country or region is: “Not to lose hope. Raising awareness can unite patients, leading to a push for better diagnosis and treatment. If we work together, there can be a change.”
With the founding of HAE Nepal and the indefatigable efforts of Dr. Bhattarai, there are reasons for genuine hope for the future. Dr. Bhattarai continues to advocate for the rights of people with HAE. He may be the only immunologist in Nepal, but he is far from alone.
HAE Research: Gifts that Keep on Giving
Debs Corcoran, HAEi’s Chief Scientific Officer, shares highlights from another excellent year for HAE research, scientific collaborations, and exchanges.
With the festive season approaching fast, reviewing the scientific gifts we have received as an HAE community in 2024 seems right. There is much to be enthusiastic about. You may have seen new data on additional potential treatment options, and research into many different aspects of living with HAE. Or read about the team of clinicians working on publishing an HAE with normal C1 inhibitor knowledge review and expert opinion on the best practice approach to diagnosing and treating this type of HAE. We are delighted to confirm this manuscript has recently been submitted for peer review in a medical journal.
21 active clinical trials are recruiting right now. In the four editions of Global Perspectives, we have brought you news on over 150 pieces of published medical research. That’s 12 pieces of new scientific knowledge for each month of the year.
Assembling the scientific community
There is a considerable amount to be proud of in how we, as an HAE community, encourage and celebrate the talents of many incredible clinical experts and pharmaceutical industry teams. And, of course, much of the research into HAE wouldn’t happen without our patient community’s motivation and enthusiasm to participate.
HAEi showcased the state-of-the-art in HAE science at two conferences in 2024. Early in the year, we met in Panama for the 2024 HAEi Regional Conference Americas. Around 100 scientists and healthcare professionals assembled at the accompanying scientific track, and 20 scientific abstracts were accepted orally or as poster presentations.
In October, the HAE scientific community came together again, in huge numbers, at the first ACARE Global Angioedema Forum. A fitting legacy to the much-missed Professor Marcus Maurer, this meeting saw 250 attendees sit down to a feast of the latest facts and figures in angioedema. 80 unique abstracts were presented, 16 as oral and 73 as posters (with some as both!), and 28 expert speakers spoke over the two days of the conference.
HAEi’s patient-driven research program
At HAEi, we don’t just offer a platform for scientific exchange; we conduct our own research to support the HAE community advocate for access to lifesaving and life-giving treatment. Here’s an update on what happened in 2024.
Kick-off conversations about HAEi Heat Map
Our Heat Map survey helps identify pockets of undiagnosed HAE and focus awareness efforts within a particular country. In 2024, the Heat Map Survey was undertaken in the Philippines, and discussions started about future studies in Thailand, Vietnam, Bangladesh, the Democratic Republic of Congo, and Egypt.Baseline burden of illness
This study turns patient experiences into evidence of unmet need. We have conducted the survey in India, Mexico, and South Africa. We are working on bringing the study to the Philippines, Vietnam, Thailand, and China.Pharmacoeconomic, socioeconomic, and quality of life assessment
The data collected can be used with Health Ministries to advocate for continued access to modern HAE therapies. At present, we have completed these studies in the US, the United Kingdom, the Nordic countries, Australia, and New Zealand. In 2024, we have an ongoing project underway in the German-speaking countries.State of Management of HAE
State of Management reports focus on the current treatment situation and its impact on people with HAE in several countries in a particular region. We use the data to raise awareness and influence healthcare and policy recommendations. In 2024, we conducted State of Management surveys in HAEi’s European regions, with SEE data presented at the 2024 HAEi Global Leadership Workshop breakout session and European Union country data used in a round table with members of the European Parliament. We are about to close our survey for the Middle East and North Africa region. We are working on a survey for the Asia-Pacific region to be presented at next year’s regional conference.A special mention: The US-validated HAE quality of life tool
A US HAEA-driven project realized the development and publication of a new, HAE-specific, US-validated quality-of-life tool. In July 2024, this was published online in the important journal Annals of Allergy, Asthma and Immunology. This new tool could potentially be validated in other countries to support advocacy for modern HAE treatments.Into 2025
In addition to the vast range of HAEi research continuing in 2025, the scientific team will return to the Asia-Pacific region in March. A dedicated scientific track will be part of the 2025 HAEi Regional Conference APAC. We anticipate exceptional HAE oral and poster presentations and lively discussions from healthcare professionals across the region.
There may not be snow piling up, at least where I sit in London right now, but great drifts of data are waiting to be analyzed. May all your evidence-based wishes come true in the New Year!
HAEi Youngsters’ Community: What a Year!
Hello everyone!
2024 has been an incredible year for the HAEi Youngsters’ Community! We have met more often, whether in-person or through online connections, leading to a stronger community than ever before.
Such a lot has happened; it is hard to pick out some highlights, but here goes…
We started the year with a successful Youngsters’ track at the 2024 HAEi Regional Conference Americas in Panama!
9 young people from across the globe have taken the reins of @haeiyoungsters on Instagram as part of the HAEi Youngsters’ Community Social Media Internship Program. Their ideas and fresh perspectives made our content more interesting and relatable than ever. Thank you to all of our wonderful interns. You have done a fantastic job!
We had the privilege of celebrating hae day :-) as a community, with everyone sharing how they marked the day. An HAEi Youngsters’ Community selfie challenge was a lot of fun, and we saw familiar and new faces from every corner of our community.
In June, we welcomed 2 new members to the HAEi Youngsters’ Advisory Group (YAG): Ania from Poland and Winona from South Africa, who have already made a huge impact.
A big project for 2024 was our new podcast, HAE – Let’s Talk. Here, we dive deep into life, adventures, advocacy, and HAE in a way that has resonated with many of you. If you want to be involved, share your story, or read/listen more – head to the Youngsters’ website https://youngsters.haei.org/ to explore the podcast. New episodes are coming soon!
Looking forward, we’re gearing up for an exciting LEAP Program 2025 after disastrous weather in Dubai ruined plans for LEAP in April this year. We offered all LEAP 2024 students the opportunity to hold their place for 2025, and in September, we opened the process for new applications for 2025. The response has blown us away! We are beyond excited to share more with you and kick off LEAP 2025 very soon.
The YAG was part of the 2024 HAEi Global Leadership Workshop (GLW). And, alongside Debs (who supports us on LEAP), I took the stage to discuss all the exciting projects for youngsters. There were meetings with Member Organization leaders from around the globe, which will lead to great collaborations in the year ahead.
The future looks bright, and we’re so excited for all that 2025 will bring, not least the return of Nevena in the new year. There’s so much to get stuck into; we’re always keen to hear from everyone in our community.
For those celebrating the forthcoming holidays, please have a wonderful, restful time. We’ll see you all in the new year!
Best wishes
VictoriaA special message from our YAG:
Dear Youngster!
May 2025 be a year filled with hope, strength, and beautiful shared moments. May health, joy, and love always accompany you. May you find reasons to smile every day, pursue dreams that inspire you, and feel the support of a community that stands by your side. Together, we can achieve anything!
We look forward to sharing more exciting experiences and seeing you all again soon.
Let’s make 2025 truly incredible!
With all our best wishes,
The HAEi Youngsters’ Advisory GroupStill haven’t joined the HAEi Youngsters’ Community?
The HAEi Youngsters’ Community is free to join and is open to young people with HAE, family members, caregivers, and friends who are part of their country’s HAE MO and are between 12 and 25 years old.
>> Head over to our website, youngsters.haei.org, and join us ☺
HAEi and ACARE: Our Partnership Grows Stronger!
HAEi’s Coordinator, Global Advocacy and ACARE, Rachel Annals, looks back at a few key highlights from the last 12 months.
2024 was a highly productive year. I worked closely with the ACARE team to deepen the links between HAEi, and the ACARE and GA2LEN teams. We held regular meetings, shared project updates, and frequently collaborated on social media.
ACARE centers
In 2024, ACARE celebrated the certification of its 100th center. This landmark also meant that you can find excellence in angioedema care in more than 40 countries. By the end of the year, the network reached 104 certified centers, with 10 more currently in the application process.
When a new center is accredited, I share this information with the relevant region’s HAEi Regional Patient Advocate (RPA), who contacts the local Member Organization (MO). This enables us to connect HAE physicians and MOs to support each other and help HAE patients and their families. The next edition of the ACARE magazine will feature an article introducing the RPAs. The article will be a valuable opportunity to showcase the incredible work of RPAs to a broader network of HAE and angioedema physicians. It will also provide HAE physicians with a point of contact with HAEi if they do not have one.
Scientific programs
ACARE has ongoing and upcoming scientific projects. One project we have supported is their HAPY initiative, which focuses on HAE in pregnancy.
HAPY is a questionnaire for patients with HAE and their physicians designed to retrospectively collect and evaluate details on the influence of pregnancy on HAE. The survey will cover the periods before, during, and after pregnancies/breastfeeding, including information on disease activity, medication, contraception, concomitant diseases, and pregnancy outcomes.
We shared information about the HAPY project with our RPAs and MOs to encourage patient participation. Using the ACARE and HAEi RPA/MO networks has enabled us to reach a broader audience for this important research.
This project is ongoing, and you can find out more or participate by contacting the project lead: Thomas.buttgereit@charite.de
ACARE Global Angioedema Forum
In October, we held the inaugural ACARE Global Angioedema Forum (GAF) in Copenhagen, drawing over 200 angioedema specialists for the two-day, information-packed event, with a special focus on HAE. In late summer, we received the tragic news of Prof. Marcus Maurer’s passing. Working closely with the ACARE team, everyone came together to ensure the event would be an exciting, informative, and fitting tribute to Prof. Maurer’s legacy and his mantra of “Never give up.”
The GAF was a huge success, with very positive feedback and enthusiasm for the next one!
2025 team planning meeting
In mid-December, HAEi’s Global Advocacy team Rachel, Fiona, and Michal, met in Berlin with colleagues from ACARE – Alice, Julia, Rebekka, Reinhardt, and Sandra. The busy, full-day meeting provided an opportunity to catch up, plan collaborative projects, discuss upcoming events, and explore initiatives and ideas for 2025. It was a productive and rewarding day, and great to catch up with each other in person. We’ll provide more details on the plans we made for 2025 very soon.
I’d like to thank everyone who helped make 2024 such a positive and productive year for ACARE. Much is still to be done, but we take heart from the progress made to date. Wishing you all a wonderful New Year!
Have you wondered how to get your HAE under control? HAE TrackR can help you!
Developed by fellow HAE patients at HAEi, HAE TrackR is an easy-to-use electronic diary designed to record your HAE treatments, HAE attacks, and the impact HAE has on your life and the lives of your loved ones.
HAE TrackR allows you to download a comprehensive report of your treatments and attacks, which can be used as a tool for you and your physician to manage your HAE.
Features of the app:
- Records your treatments (preventative, on-demand and clinical trial medication)
- Records attacks and developments/improvements of attacks
- Has a smart reminder functionality for prophylactic treatments
- Is endorsed by ACARE for its ease of collecting and using data and comprehensive reporting
- Is safe and secure, product and company neutral with no commercial interests
News from HAEi Countries Around the Globe
News from Argentina
From Alejandra Menendez, HAE Argentina
2024 was a challenging yet very productive year for our HAE community. Undoubtedly highlighted by two wonderful international events, the 2024 HAEi Regional Conference Americas and the 2024 HAEi Global Leadership Workshop and ACARE Global Aniogedema Forum 2024 set up the tone for a fantastic year.
The beginning of the year was enhanced by the superb 2024 HAEi Regional Conference Americas in Panama, which provided a unique opportunity for sharing and learning and gave us the chance to meet patients from all over the Americas, thus fostering emotional and social support. Under the conference’s motto, TAKE ACTION, our representatives were enriched by the multiple presentations and activities that took place during two awe-inspiring days.
hae day :-), on 16 May, was yet another interesting highlight of the year. As usual, different activities were organized to promote awareness of HAE. But what made this hae day :-) extremely special was the active involvement of our youngster community. Our young group gathered not only to adhere to HAEi’s campaign “Walking for HAE” but also to organize an informal Get-Together, which ended up with a fantastic, fun-filled “Escape Room game” where our youngsters had to find clues, solve clever puzzles, and crack codes all related to HAE. It was amazing to realize how well-informed our younger patients are. We are very happy to see that the HAEi’s Leap program served as a magnificent starting point for getting our youngsters involved.
October found some of our members traveling to Copenhagen, Denmark, to participate in the first Global Angioedema Forum and Global Leadership workshop. The wealth of information shared during this combined event made this quite a unique experience for our group. We got back home inspired and motivated to keep on doing our best to improve HAE patients’ quality of life.
Finally, the end of 2024 found us celebrating another very important milestone for the Argentine patient community: the approval and marketing authorization in our country of yet another prophylactic treatment for HAE, making it now the 3rd medication available to prevent HAE episodes in our country. What better news to close a productive year than to expand our treatment options?
As we move forward to a New Year, we hope 2025 will continue to show greater advances in the study and management of Hereditary Angioedema, with new treatments that result in improved quality of life for all HAE patients around the globe.
May 2025 find our local organization strengthening its advocacy efforts, and may our patients continue to improve access to modern, safe, and effective medications.
May the New Year bring boundless hope for the future of HAE patients.
News from Australia and New Zealand
A Year of Growth, Connections, and Inspiration: HAE Australasia’s 2024 Highlights and Goals for 2025
It’s been a fantastic year for HAE Australasia, filled with exciting developments, new faces, and powerful connections that have made 2024 a year to remember. From expanding our team to hosting dynamic webinars, growing our membership base, and making impactful connections on the global stage, we’ve truly stepped up our efforts to support people living with HAE across Australasia.
A Year of Growth and Expansion
One of the most exciting highlights of this year has been the growth of our membership and the increased capacity to connect with more people than ever before. Thanks to the hard work of our dedicated team, we’ve ramped up our social media presence and armed our members with the tools, tips, and information they need to live their best lives with HAE. We’ve strengthened our online presence, ensuring that vital resources are just a click away for those who need them.
HAEi Global Leadership Workshop, Copenhagen
In October, 5 members of our 6-strong team ventured to Denmark for the 2024 HAEi Global Leadership Workshop, where we had the opportunity to forge new connections with HAE advocates and medical professionals worldwide. This inspiring experience honed our advocacy skills and introduced us to a new Relocation Tool, a Conference Planning tool, and the amazing work of the HAE Youngsters and their fabulous podcast. We left Denmark with fresh perspectives, new friends, and a renewed passion for advancing equal care for people with HAE in Australasia.
Webinars That Make a Difference
This year, we were proud to launch a successful three-part webinar series to keep our members informed and engaged. Despite the challenges of spanning 2 countries and up to 7 time zones, we reached more than 60 participants (huge for our membership size), sharing essential knowledge on topics like HAE Basics, Women’s Health, and Children’s Health. We’re committed to providing our community with the latest tools, research, and support to help manage HAE and improve quality of life.
What was new in 2024?
Early in 2024, we introduced new videos to our website sharing the powerful stories of teenagers and young adults with HAE, highlighting how access to modern prophylactic treatments transformed their lives. These videos revealed the profound improvements in quality of life for those with access to preventative therapies, contrasting life before and after treatment. A physician’s perspective reinforced the benefits of managing HAE proactively rather than waiting for attacks. Currently, only Australia offers access to these modern therapies in the region. By showcasing these experiences, we aim to strengthen our advocacy efforts and drive change for broader access to preventative treatment options.
In 2024, we also overhauled our website, adding new pages that better serve our community. Our new Youth page and linked toolkit offer a wealth of resources for younger members, while our Children’s page now includes valuable links to the Brady Club and the Brady Club Activity Books. We also launched a dedicated Clinical Trials page to inform members about ongoing regional research and trials and a Webinar Hub where members can submit suggestions for future topics.
To help us manage the growing workload, we were thrilled to welcome a new Operations Coordinator to the team in March. This role has been instrumental in overseeing social media, website updates, and other operational tasks, allowing our team members to focus on their areas of expertise.
Finally, we were honored to have Dr. Alberto Pinzon Charry join us this year to share insights on children with HAE. Prof. Connie Katelaris has continued supporting our webinars, providing invaluable expertise and keeping us informed about the latest clinical trials. Our ongoing collaborations with physicians have been vital to our success this year.
Looking Ahead to 2025
The momentum doesn’t stop here! In 2025, we’re excited to continue expanding our reach and growing our membership base. We’ll use our social media platforms and revamped website to connect with more individuals across Australasia, especially focusing on youth engagement. We recognize the importance of supporting younger members and helping them feel connected and empowered, and we plan to dedicate more resources to this in the year ahead.
Another major goal for 2025 is raising funds for in-person patient meetings. We’re thrilled to have secured several travel grants to send a strong group of members to the 2025 HAEi Regional Conference APAC in Manila this March. We can’t wait to share what we have learned and successes with you at the end of next year!
Looking Forward to Even Greater Things
We’ve accomplished so much in 2024, and we’re energized for the year ahead. With a growing team, an expanding network of supporters, and a community of people with HAE who continue to inspire us daily, we’re confident that 2025 will bring even more exciting opportunities to make a difference. Here’s to another year of growth, connection, and progress for HAE Australasia!
News from Bangladesh
Bangladesh has been a member country since 2019. Angioedema Bangladesh is the official name of the member organization. The patient group now has 25 members.
As our roadmap, we are focusing on educating the physicians and raising awareness among the patients on the management of HAE. Consequently, we arranged a webinar on 16 November of this year. It was a very significant event in which almost 40 local and international physicians and specialists participated. It potentially helped the doctors and patients with HAE management, treatment, and care.
In the future, we are committed to arranging patient meetings, conferences, and webinars to provide a better understanding of HAE and its management.
News from Brazil
Abranghe was present at several events during the year – see images below
- Participation in the LI Brazilian Congress of Allergy and Immunology in the city of Salvador-BA. Our stand promoted the work of Abranghe and AEH.
- Publication of joint work by Abranghe with CSL and Dr. Pedro Bianchi on 9 November 2024.
Raquel de Oliveira Martins, HAE Brazil, is co-author of the article Unmet needs in the management of hereditary angioedema from the perspective of Brazilian patients. The open-access version of the article, containing full bibliographic details, is now available online.
News from Canada
We concluded our Global Perspectives #3 Newsletter by mentioning our October Patient Information Update. We can now report that on Saturday, October 19th, Michelle Cooper (President), Kerstyn Lane (Regional Director), Daphne Dumbrille (COO), and Heather Dow (Events and Management Plus) traveled to Halifax, Nova Scotia, to host our Update. We enjoyed a very informative and interesting presentation by a local allergist and immunologist, Dr. Pascale Clark. First, Dr. Clark explained how Shared Decision Making (SDM) between a patient and their physician ultimately leads to patients receiving the best possible care. She encouraged our members to ask themselves important questions before their next appointment so they can use the time with their physician wisely (What are my concerns? What information do I need to make good health decisions?). She continued her presentation by discussing the current HAE treatments in Canada and focused on the newest treatment to the Canadian market: Orladeyo, the first oral HAE treatment. We want to thank Dr. Clark for sharing her expertise with us on a beautiful Saturday afternoon, and we also want to thank our members, both in person and online, who joined us to learn and connect. We loved seeing members, both new and experienced, at the Update.
Knowing Dr. Clark was going to speak about SDM, we waited until after the Patient Update to share our newest instructional video. With funding from Takeda Canada, we developed a video on SDM designed to explain the merits of SDM through a conversation between one of our members, Erin, and her physician, Dr. Adil Adatia. We are very proud of this new addition to our website, so we encourage you to please visit our Resources page to watch the video.
In early November, Dr. Derek Lanoue from the University of Ottawa invited Michelle to present to his class of first-year medical students. In his lecture titled “Intelligent Advocacy in the Context of the Canadian Healthcare System,” Michelle first explained HAE as a disease and then explained why HAE Canada’s advocacy is important (to increase awareness, increase access to therapies, and address inequalities across the country). Not only was it rewarding to be able to discuss the importance of patient advocacy and why it needs to exist in Canada, but it was also an amazing opportunity to expose over 150 first-year students to HAE!
Michelle, Daphne, and Kim Speiss (Regional Director) boarded another plane to attend the Canadian Society of Allergy and Clinical Immunology (CSACI)’s Annual Scientific Meeting in Banff, Alberta, from November 7th to 9th. It was amazing to see 11 posters displaying scientific research on HAE, reminding us how fortunate we are that there are many dedicated physicians and researchers across Canada who complete very important HAE research in Canada. It was wonderful to be present at the Canadian Allergy, Asthma and Immunology Foundation (CAAIF) Gala (CSACI’s foundation) when it was announced that Dr. Adil Adatia won the CASP-CAAIF research grant. The Canadian Angioedema Scholarship Program (CASP) Foundation was founded by HAE Canada in 2019 to administer funds for HAE research in Canada. Congratulations to Dr. Adatia, who is the department head of the ACARE center in Edmonton, Alberta.
On November 14th, we held our virtual Annual General Meeting, where we voted in our 2024-2025 Board of Directors:
- Michelle Cooper (President, Ontario Regional Director)
- Carmen Craciun (Treasurer / Secretary)
- Kerstyn Lane (Director at Large)
- Martine Paquette (Quebec Regional Director)
- Kim Speiss (Central Regional Director)
We want to acknowledge the contributions of past president Jacquie Badiou as she has completed her term on the Board of Directors. Jacquie dedicated more than 10 years to advocating for new treatments for patients with HAE in Canada as president and past president of HAE Canada, which has led Canada to have 4 effective prophylaxis treatments and 2 acute treatments approved, and many more are in the pipeline. Under her leadership, the organization and the board grew and developed to become recognized internationally as one of the leading HAE patient organizations. She fostered excellent relationships with HAEi, which has led to invaluable support and collaboration, particularly in our advocacy efforts. We want to extend a huge thank you to Jacquie for all her work and dedication to HAE Canada over the years she sat on the Board.
We are absolutely thrilled to report that the first oral preventative treatment is now available to patients living in British Columbia and Alberta. Many years of dedication and effort from BioCryst Pharmaceuticals, researchers, physicians, and patients (particularly patients who participated in the clinical trials!!) have allowed Orladeyo to become available in Canada. We are proud we played our part by providing Canada’s Drug Agency with a patient submission to support reimbursement for this treatment. Thank you to the BC and Alberta governments for being the first to make Orladeyo available to HAE patients. We are confident it will not be long before the other provinces and territories follow suit.
On November 26th and 27th, Michelle and Daphne were in Montreal, Quebec, to attend a conference titled Teaching Pigs to Fly… or How to Leverage $1.5B Rare Disease Drug Strategy into Value-Based Comprehensive Rare Disease Plan. The conference was co-hosted by the Canadian Organization for Rare Disorders (CORD) and Quebec based organizaiton Regroupement québécois des maladies orphelines (RQMO). The conference focused on how Canada can get a value-based return on the $1.5 Billion that is dedicated to the National Rare Disease Drug Strategy. The conference made it clear that the money cannot be spent only on treatments for rare diseases but rather on many aspects of care, such as science, research, registries, and diagnostic tools to speed up diagnosis and drug access. It was a very informative conference, and we are grateful that CORD is working hard for all Canadians with a rare disease.
To end this final newsletter of 2024, we’ve been asked to share our highlights and our hopes for 2025.
Our highlights from this past year:
- Attending 2 of HAEi’s 2024 conferences: the 2024 HAEi Regional Conference AMERICAS in Panama and the 2024 HAEi Global Leadership Workshop and ACARE Global Angioedema Forum 2024 in Denmark. It was amazing to learn about new therapies to treat HAE and effective methods to attract new members, connect with HAE communities in countries around the world, and discover how others are raising awareness of HAE.
- Reimbursement for ORLADEYO has been achieved in two provinces so far!
- Successful light-up campaign for HAE Day of the CN tower in Toronto
Our hopes for advocacy and people with HAE in Canada 2025:
- Access to modern medicine for all types of HAE in Canada, including pediatric patients
- Achieve a positive review from Canada’s Drug Agency to extend access to and reimbursement for people with HAE with Normal C1-INH to icatibant therapy (final recommendation decision is pending)
- Increase awareness of HAE through media and events
- Easier ways for diagnosis and access to treatment for ALL HAE types
- Updated emergency resources
- More therapies approved for reimbursement in Canada
- All provinces sign agreements for reimbursement of Orladeyo and for icatibant for nC1-0INH patients
- Publication of an article based on our National Report Card data since 2017
- Attend HAEA summit in July
We want to wish everyone happy holidays, and we hope everyone will have the opportunity to spend some quality time with loved ones.
News from Cuba
My greetings from Cuba with the desire to continue being an active part of the great HAEi family.
2024 has been a fruitful year for HAE Cuba. We are a young organization that wants to acquire work experience and continue to be involved in the International patient Community.
- Our organization’s first participation in the Regional Conference of the Americas, represented by three patients and a doctor, marked an important turning point in our desire to establish ourselves as a country under the HAEi umbrella.
- Arriving in Copenhagen, represented by a patient and two doctors, and participating in both world forums was an unforgettable experience that gave us great relationships and teachings.
- We created our WhatsApp group for patients. We started updating the national registry with the support of the Institute of Hematology and Immunology of the Ministry of Public Health of Cuba (the medical center responsible for the disease in the country), which has allowed us to realize that the Cuban HAE family is larger and is dispersed throughout the island, that we need to be more united to face the challenges that the disease imposes on us and to promote solidarity among ourselves. This has undoubtedly been the fundamental achievement of our member organization this year.
We are always grateful to our regional advocate, Javier Santana, and other member organizations from other countries with which we maintain excellent communication.
News from Czech Republic
HAE Junior marks its 5th anniversary with a special digital campaign
HAE Junior patient organization announces the launch of a birthday digital campaign to celebrate 5 years since registration. Together, we want to remember the main achievements and milestones our association has reached with the support of patients, their families, healthcare professionals, and partners in the Czech Republic and abroad.
Starting in December, we will reveal anniversary wishes and messages received from children and teenagers with HAE, their parents, healthcare professionals, and partner organizations every day. These messages reflect, from various perspectives, the importance of HAE Junior’s activities for the benefit of HAE patients and their loved ones. Thus, the campaign is an opportunity not only to celebrate but also to express mutual support and inspiration among community members, which is in line with our organization’s mission.
The digital part of the campaign will run on both HAE Junior’s social media (Facebook, Instagram, and LinkedIn) and on the anniversary website, where we are opening a virtual advent calendar in December. The campaign, which is to continue until Christmas, will also include printed materials (in the Czech language only). Wishes from children, young patients, and other community members will be unveiled one by one, offering a personal insight into the activities and support HAE Junior provides.
We tHAEnk everyone who sent us their wishes and messages for this very special campaign!
The project is carried out with the support of our partners: Amberplasma, KalVista, Pharvaris, Swixx Biopharma, and Takeda, Czech Republic.
News from Denmark, Norway, and Sweden
From HAE Scandinavia
On 30 November, HAE Scandinavia held a meeting with patients and caregivers in Aalesund, Norway, with Norwegian members. The discussion focused on living with HAE across generations, the significant progress in HAE treatments, and the promising new treatment options on the horizon.
Living with an HAE diagnosis should no longer limit one’s ability to live a life without restrictions. That is why it’s essential to support HAE Scandinavia to ensure ongoing awareness and interest in HAE among:
- Doctors and nurses, who can provide the best possible care,
- The pharmaceutical industry, which develops new medicines, and
- Authorities, who must understand the positive impact of approving new treatments that offer better control and improved outcomes for HAE patients.
This collaboration creates the best foundation for living a full life without limitations.
HAE Scandinavia is a community for everyone whose lives are touched by HAE, including patients, families, friends, and supportive colleagues. The organization offers tools to make daily life with HAE easier:
- HAE TrackR, which helps you track your HAE and provide documentation for your doctor.
- HAE Companion, which ensures your emergency card is always within reach when traveling.
- SumsUp, your pocket companion, reminding you that you’re never alone with HAE.
- LEAP, an educational program for young people who want to make a difference. In 2025, a young participant from Norway will work on the project: “How do we find young people with HAE in Scandinavia and motivate them to join the HAE community?”
HAE Scandinavia extends heartfelt thanks to everyone who attended the meeting in Ålesund and to all those supporting the organization. Remember, you can always reach out to HAE Scandinavia – we are here for you!
News from Hungary
On November 30, 2024, the first face-to-face club meeting of the Hungarian Patient Organization after COVID-19 was held. The location was the clinic of the Semmelweis University of Medicine. There are 220 registered patients in Hungary, of which 165 are association members.
The event was attended by 50 people, 30 of our fellow patients, and representatives of pharmaceutical companies from CSL Behring, Pharming, Swixx BioPharma, and Takeda. Our doctors also participated in the event: Prof. Dr. Henriette Farkas is the head of the Hungarian ACARE center; her right hand Dr. Hanga Horváth; Lilian Varga, head of the Complement lab; Dr. Beáta Visy is a doctor at the Madarász utca Children’s Hospital, who helps the Hungarian HAE center in many HAE trials, Prof. György Harmat, who was the general director of the Heim Pál children’s hospital and continuously helps and has helped with the care of HAE children, and Judit Bali, who brings together and coordinates the work of the Hungarian ACARE center.
The program of the event consisted of the following agenda:
The Patient Organization welcomed the participants and thanked them for their interest and for taking the trouble to participate. Dr. Prof. Henriette Farkas also greeted the participants.
A report on the patient organization’s work and financial situation this year, as well as the tasks ahead of us next year. Among these, there are two important tasks: the renewal of the foundation document of the association, which is already more than 25 years old. The patient organization must comply with the new legal requirements. Among our other tasks, we can mention participation in tenders and their preparation…
We also reported on the 2 most important events: The Day of Rare Diseases, held in Sopron in February, and the GLW and GAF, held in Copenhagen in October.
Then, Dr. Hanga Horváth summarized the research results achieved in the past year and the current events related to drug supply.
Then, there was a short discussion between patients and doctors about current issues and topics of interest to everyone. We agreed that such events will still be needed in the future in order to strengthen each other …
News from India
From Shaibal Guha, HAE India
First in-person patients association meeting of HAEIPA at Hyderabad, India
Hi, I want to send a write-up from India about patient association activities.
After getting the HAE India Patients Association registered a few months back, we organized our first in-person regional Patient meeting in Hyderabad for patients living in the southern part of the country.
Despite the fact that it was arranged at a very short notice of 2 weeks, it was well attended, and we had about 50 participants (patients and caregivers) sharing their stories and learning from the experts.
The meeting was initiated by Dr. Shaibal Guha, founder & treasurer of HAEIPA, welcoming all the participants.
The schedule of the meeting and the need for having a patient organization were explained to all by Ms. Pravalika, the Hon. President of HAEIPA.
Dr. Spurthy Reddy Chitta, a pediatric rheumatologist of Hyderabad, sportingly took time out to come over and give tips about HAE care in children.
Dr. Anuradha Udumudi, the founder of Genentech, a genetic diagnostic and research company, was kind enough to spare time to talk about genetic diagnosis, genome sequencing, and prenatal diagnosis of HAE.
The meeting was blessed by the good wishes of Ms. Fiona Wardman, the executive vice president of Global advocacy of HAEi. She talked about the various activities being done by HAE International.
Patients were further enthused by the joining of Ms. Fanny Schappler, the regional patient advocate for South Asia, who explained to them the meaning and importance of advocacy.
The presence of Dr. Ankur Jindal, professor of pediatric rheumatology at PGI, Chandigarh, and the founder of HAESI, the nodal doctors association dealing with HAE in India, was the icing on the cake. He painstakingly took the patients’ queries and answered them in simple language.
As a whole, pre and post-lunch sessions were very well attended by the patients, both local and from far off, and excited discussions continued till the evening, when it was time to conclude.
Dr. Shaibal Guha thanked the participants, as well as the sponsors (Takeda Pharma), for a very successful first patient meeting ever since the national association was registered.
News from Indonesia
Dear HAE community, HAE Indonesia has made a few small strides in 2024 towards better awareness for HAE in Indonesia.
To share our experience and also to learn about others’ experiences, I met up with Ms. Suchitta Shee Kengtanyagarn (henceforth Shee) from HAE Thailand and also participated in a virtual roundtable session organized by Deloitte, together with Ms. Shee and Ms. Makiko Matsuyama, President of HAEJ, to share the realities and challenges of HAE in our respective countries. This is the first time HAE Indonesia has participated in such activities together with other member organizations in the region.
HAE Indonesia is also connecting and working with medical students in Surabaya, Indonesia, to introduce them to HAE and to assist them in presenting about HAE in their seminars to help raise awareness and interest in the condition in the medical schools.
For 2025, we want to help more people with HAE who remain undiagnosed. Increasing awareness about the condition among the public and health professionals will move us closer to shorter delays in diagnosis. The long-term goal is to improve the availability and access to treatment in Indonesia and hopefully help bring treatments to other countries in the region.
News from Japan
From Makiko Matsuyama, HAE Japan
First of all, 2024 marked the 10th anniversary of the HAEJ’s establishment! It’s hard to believe that it’s already been 10 years since our launch. This year has been a significant one for HAEJ, as we’ve taken on new challenges and actively participated in academia.
Starting with hae day :-) in May, the DISCOVERY Consortium, an industry-academia HAE consortium, and HAEJ collaborated to conduct a nationwide light-up campaign! We decided on lavender purple as HAE’s theme color and were able to have 22 symbolic towers and facilities across Japan illuminated. Among them, we visited Yokohama City and Kumamoto City, which supported hae day :-) as municipalities, to greet them and discuss future collaborations.
We also actively exhibited at medical conferences, and I gave a speech at the conference as a speaker representing the patient association. After the lecture, many doctors visited our booth to talk, allowing us to network with numerous doctors and gather information from various regions. Perhaps participation in such conferences can be a reference for other countries. We also actively learned and exchanged ideas from the perspective of genetic counseling. We need to continue discussing how to effectively utilize the support of genetic counselors and communicate this to our patient association members.
We also appeared on 2 TV programs! This was also thanks to our close collaboration with pharmaceutical companies. Through media roundtable events and direct contact with reporters, we achieved media exposure by continuing our steady appeals. We also participated in a project to increase the number of doctors who can diagnose HAE in Vietnam, together with the Japanese patient association representative. Since Japan already has fairly advanced treatments among Asian countries, we believe that it can serve as a model and provide support for other Asian countries. I hope we can continue to actively communicate and share best practices.
News from Mexico
Highlights of 2024
- On October 30, 2023, the Chamber of Deputies of Mexico, by decree, declared May 16 of each year “National Hereditary Angioedema Day”. For this reason, May 16, 2024, was officially celebrated in Mexico, for which the Symposium: “NATIONAL DAY OF AEH, AN ANTHROPOLOGICAL VISION” was held. In which doctors, patients, caregivers, and authorities from the health sector participated, as well as the National School of Anthropology and History of the National Autonomous University of Mexico. >> You can read more about HAE Mexico’s activities for hae day :-) in the ‘hae day :-) 2025′ feature.
- Creation of the AMAEH award in recognition of patients, caregivers, health sector personnel, and anyone who contributes through their courage, tenacity, and resilience in the face of AEH. The first three prizes were awarded on May 16, 2024.
Hopes for 2025
- Accredit an AEH center in Mexico.
- Start with the national registry of patients.
- Have an AMAEH website.
AMAEH News
- Launch of ORLADEYO in Mexico on August 17, 2024
- Awareness meetings at the Mexican College of Allergy and Clinical Immunology.
New AMAEH Logo
At the initiative of AMAEH, the Mexican Group of Specialists in Hereditary Angioedema (GEMAEH) was formed.
News from Netherlands
It’s hard to believe that we’re already wrapping up 2024. Time seems to have flown by. So many great things have happened since January. We’d love to share a few highlights with you.
At the beginning of the year, HAE The Netherlands identified some focus points for 2024. We wanted to grow our network, we wanted to take a step forward in providing information about HAE, and our most important focus point was bringing the community together.
We managed to be successful on all 3 points.
Our network grew significantly. We managed to build relationships with several HAE specialists, strengthened our international network by connecting with several sister organizations, and got in contact with all the pharmaceutical companies within the HAE community. Besides that, we built a network within the Dutch Rare Disease Community. We believe in partnership to improve the lives of people living with rare diseases, particularly those with HAE. We also became members of RIPAG, the patient advocacy group of ERN-RITA, the European Reference Network for Rare Immunological Diseases. Within this network, we work together with HAE Junior, our Czech sister organization, to bring the HAE patient perspective into the network.
In the field of providing information to the Dutch HAE community, we celebrated the first edition of our own magazine. This is a magazine that provides articles about HAE, our organization, and our HAE specialists. Furthermore, it includes patient stories. We’re hoping to publish this magazine twice a year. We also completed the Dutch and Belgian translations of Understanding HAE and Women with HAE. Thanks to the hard work of the HAEi team, these translations will soon be available on the website. In 2025, we will have both booklets printed to distribute to the Dutch HAE community.
We also managed to bring the Dutch HAE community together for a fun day full of informative presentations and peer support. On 16 November, we organized our annual patient meeting. We saw a significant increase in the number of participants compared to 2023. We are pleased to see this significant increase because it is important and beneficial for people living with HAE to come together.
On this day, we enjoyed excellent presentations about the pathophysiology of HAE, ethical dilemmas in research, and current and future treatment options.
The interaction between the speakers and the participants was very special. So many good, informative questions were asked, and we ran over our planned time schedule. We were very pleased that all the speakers stayed to join us for lunch. During lunch, we observed a lot of fun conversations between speakers, patients, and caregivers. There was also a lot of peer support going on. Bringing the community together is so important.
In the afternoon, we enjoyed a special presentation from our RPA, Maria Ferron. She inspired the participants to become advocates and stated that it’s important that patients not only advocate for themselves but that they help the patient organization to advocate for the whole community. Maria knows how to bring the HAEi perspective to the countries under her umbrella. She also shared with us some preliminary data on the management of HAE in Europe study HAEi did this year. We’re very grateful that she and Debs were willing to share this with us, even though the data is still being analyzed. We can’t wait to read the finished report. All in all, it was a fun day full of enjoyable conversations. Next year, we’re planning to organize more frequent meetings to bring our community together.
Looking ahead to 2025, we express our hope that the global HAE community will become even more connected. By coming together, we can collectively achieve our goal of a normal life for all patients.
To conclude, we would like to wish everyone happy holidays.
News from Serbia
Symposium on Rare Diseases: Advancing knowledge and treatment options
From November 15 to 17, the Fourth Symposium on Rare Diseases took place in Divčibare, Serbia, organized by the Serbian Association for Preventive Pediatrics (UPPS). The event brought together medical experts and patient associations to exchange knowledge and improve the diagnosis and treatment of rare diseases in Serbia.
One symposium topic was hereditary angioedema (HAE), a rare genetic condition that causes recurrent episodes of swelling. Several expert presentations emphasized the latest advancements in the treatment and care of HAE patients.
Assistant Professor Dr. Radovan Mijanović and Dr. Dušanka Marković, long-time collaborators with the HAE Serbia Association, spoke about HAE at this event.
Assistant Professor Dr. Radovan Mijanović delivered a lecture titled “The Efficacy of Lanadelumab in Reducing Attack Frequency and Improving AE-QoL in HAE Patients in Serbia,” showcasing the positive impact of this therapy on patients’ quality of life.
Dr. Dušanka Marković presented “The Future of HAE Therapy – Expectations and Hopes,” exploring innovative treatment approaches and prospects for managing the condition.
Jovana Cvetković Lazić, president of the HAE Serbia Association, shared insights into patients’ challenges and emphasized the importance of collaboration between healthcare professionals and patient organizations.
“The symposium offered a valuable opportunity to share information about HAE and to raise awareness of this condition. We want to thank the organizers, Dr. Dušanka Marković and Doc. Dr. Marko Jović, the president of UUPS, for their excellent organization and for allowing us to be part of this important event,” said Jovana.
The symposium emphasized the need for continued education and cooperation to enhance care and support for individuals with rare diseases.
News from Singapore
From Lim Yong Hao, HAE Singapore
There were 2 key developments for HAE Singapore and HAE patients in Singapore.
Firstly, a dedicated HAE Clinic was set up in the early part of 2024 at Tan Tock Seng Hospital. The clinic also set up referral protocols with other hospitals in Singapore to refer potential patients to this clinic. This move demonstrated the recognition of HAE within the medical community and hopefully helped to consolidate resources, knowledgeable doctors, and patients at one locale, as well as the first step towards an ACARE Centre in Singapore.
Second, HAE Singapore is now working together with other rare disease groups under the banner of Rare Diseases United to share resources, collaborate on initiatives, and have strengths in numbers. HAE Singapore has learned much from this partnership and will be participating in various activities to push the agenda for better data and decision-making for rare diseases and a call for a strategic plan for rare diseases in Singapore.
Our hopes for 2025 are the same as 2024. We hope to reach out to all HAE patients and caregivers in Singapore. We have been slowly building up the membership for HAE Singapore, but we hope to have a big enough community so that we can have regular activities for both HAE patients and caregivers. We are looking to bring modern treatments to Singapore. There are many opportunities to hopefully bring generic icatibant to Singapore, support registration of new treatments such as sebetralstat, and participate in clinical trials for deucrictibant. 2025 will hopefully be a good year for HAE patients in Singapore.
News from South Africa
HAE SA 2024 YEAR IN REVIEW
Our organization has had a busy, productive year raising awareness for HAE!!
In the run-up to Rare Disease Day 2024, we released a series of 6 patient video stories, with our patients highlighting the difficulties in their journeys to getting a diagnosis and the importance of having a strong patient support network. Our annual patient meeting in Cape Town on the 6th of April was attended by doctors and patients from across the country. For the first time, we were able to offer travel grants to our patients and caregivers, ensuring record attendance and a hugely successful, informative event. We have also hosted a number of webinars for doctors and patients, including “Women with HAE”, on the 21st of November, where Prof. Henriette Farkas presented an informative session on the topic. On hae day :-), we launched our mental health program, “Mental Health Matters”, starting with a series of 6 videos., Our program is ongoing, and we hope to offer continued support for our patients and caregivers.
Our team attended the 2024 HAEi Global Leadership Workshop in Copenhagen in October, and we look forward to seeing our colleagues and friends at the EMEA Conference in 2025.
HAE S.A. has made significant progress over the past year and could not have done so without the dedication of our physicians and the support and guidance of our colleagues and friends at HAEi and within the greater rare disease community. As we look back at another successful year of HAE advocacy, we look forward to the challenges that face us in the new year.
News from Switzerland
3 Highlights from 2024
1: Patient Meeting
On Saturday, April 20, 2024, we held our HAE patient meeting at Zurich Airport
These HAE experts will be happy to answer your questions in a panel discussion
- Prof. Dr. med. Dr. Phil. Walter A. Wuillemin, HAE expert, Lucerne Cantonal Hospital
- PD Dr. med. Urs Steiner HAE expert, Department of Immunology, Inselspital Bern
- Dr. med. Christina Weber, HAE expert, University Hospital Zurich
- Dr. med. Isabel Morales, HAE expert, Inselspital Bern
- Prof. Dr. med. Dr. Phil. Sascha Zeerleder, HAE expert, Lucerne Cantonal Hospital
- HAE patients share experiences and give valuable tips on medication use
2: hae day :-)
The Swiss HAE Association is surprising its members with this present to mark the occasion. This flying disc symbolizes active leisure activities, outdoor fun, and solidarity with those affected by hereditary angioedema.
3: Virtual, interactive HAE action week for and with patients
Together with the German and Austrian self-help groups, we are organizing this virtual, interactive HAE action week from May 14, 2024 – May 16, 2024
- Tuesday, May 14, 2024: The doctor-patient conversation with Dr. Sabine Altrichter, Linz
- Wednesday, May 15, 2024: Growing up with HAE with Dr. Christina Weber, Zurich
- Thursday, May 16, 2024: The female side of HAE with Dr. Inmaculada Martinez Saguer, Mörfelden and Prof. Bettina Wedi, Hanover
Our hopes for the advocacy group and people with HAE in your country in 2025
- CSL Behring expects approval in Switzerland for the active ingredient Garadacimab by the end of 2024.
- KalVista submitted further marketing authorization applications for an oral treatment for acute attacks in September 2024. The marketing authorization applications were submitted via the Access Consortium to maximize cooperation between the various countries’ regulatory authorities and support a timely review process. KalVista has entered into a four-party agreement on the division of labor between the MHRA (UK), Swissmedic (Switzerland), TGA (Australia) and HAS (Singapore). However, the MAA processes take time. The fastest MAA processes usually take at least 1 year.
Updates from the member organization
- We attended the 2024 HAEi Global Leadership Workshop in Copenhagen with three members of the Swiss HAE Association. We would like to thank you again for the excellent organization.
- On November 8, we held our 23rd HAE general meeting. We could hold the meeting quickly, and all agenda items were approved.
Annual program
- December 3, 2024: Christmas cards & swelling calendar sent
- March 2025: Invitation to the HAE patient meeting on May 24, 2025
- May 24, 2025: Swiss HAE patient meeting with lectures by HAE experts, tour of Zurich train station
- May 2025: Virtual HAE-DACH action week (online)
- May 16, 2025: hae day :-) – Special campaign for our members
- Autumn: Possibly llama trekking; International HAE patient meeting for patients
- October 2025: Invitations sent for the 24th general meeting of the Swiss HAE Association
- October 2025: Publication of the 9th newsletter, ‘News from the Swiss HAE Association’ (German)
- November 7, 2025: 24th HAE general meeting
News from Taiwan
From Jung-Ting Chen, HAE Taiwan
This year, in addition to holding lectures in the North, Central, and, South, East Districts like last year and 2 patient meetings.
Although not many patients participated in the event, we can see that new patients are willing to come forward and share, which I think is great.
We still hope that maintenance injections with relatively few side effects will become popular as soon as possible in 2025.
News from UK
As the year comes to a close, we are still extremely busy liaising with the NHS, medical professionals, and pharmaceutical companies to support our day-to-day work for HAE patients and their families.
We have worked closely with pharmaceutical companies, supporting new medications going through clinical trials and licensing/approval. Overall, the arrival of these new medications in 2025 and 2026 holds great promise for enhancing patient care and contributing to better health outcomes for HAE patients in the UK.
New regulations from NHS England are currently in progress, specifically aimed at collaboration with the Rare Disease Network. We hope this initiative will lead to earlier detection and more accurate diagnosis. The anticipated outcome of these efforts is to improve the overall healthcare journey of those affected by Hereditary Angioedema, ultimately resulting in better treatment and care.
An increasing amount of effort is being dedicated to expanding the scope of research and data collection of both HAE-Normal C1 and Acquired Angioedema to help establish diagnosis and treatment. We have been supporting this research as much as possible because we are having an increasing number of patients with these types of angioedema reaching out to us for advice and support.
We recently completed a nationwide mailout campaign, sending letters and posters about HAE to every GP practice in the UK. The letters explained the condition, and the posters were intended for display in patient waiting areas. The goal was to raise awareness of HAE among both healthcare providers and the general public, and also with the hope of reaching those who may be undiagnosed.
We look forward to an exciting and productive 2025 and wish you all good health and happiness.
News from USA
A Milestone Year for the HAEA Community: 2024 Year in Review
As the year draws close, we reflect on the collective success of our HAEA community in 2024. This year was marked by progress, innovation, and shared achievements that have paved the way for an even brighter future.
Highlights of 2024 at the US HAEA include:
- An HAEA-initiated research project that included well over 500 HAEA friends has resulted in a ground-breaking HAE-specific tool that measures Quality of Life for people with HAE in the United States. The prestigious medical journal–Annals of Allergy, Asthma, and Immunology–recognized the value of this project by publishing an article documenting the development and testing of this groundbreaking tool. The publication can be viewed by clicking HERE.
- HAEA Health Team Advocates offered our community invaluable assistance in resolving insurance denials and delays, guiding and following up on referrals to expert HAE physicians, and providing answers to countless HAE-related questions.
- This year, we introduced a new scholarship opportunity for Aspiring Healthcare Professionals, designed to provide financial support to those in the HAE community pursuing a career in any healthcare-related field.
- 250 attendees celebrated academic achievement and community spirit at the 2024 HAEA Scholarship Gala. This event reinforced the HAEA’s commitment to empowering and supporting the next generation of leaders. You can watch a recap of this event by clicking HERE.
- During the 2024 Virtual HAE IN-MOTION® and awareness events in Boston, Dallas, and Chicago, over 350 participants walked over 10,000 miles to raise HAE awareness in their communities.
- This year, we launched the HAEA academy, an online platform that offers a range of free online courses aimed at supporting HAEA friends at every stage of their HAE journey. You can access courses on topics like clinical trials, Medicare basics, the HAEA Shared Decision-Making Tool, and more by clicking HERE!
- In 2024, we hosted 9 HAEA Treatment Education Series live and on-demand webinars – designed to serve and inform the HAE community about available treatment options – that registered over 50,000 views.
- With over 21,000 plays, the HAEA Podcasts, including HAE Speaks and #BeyondHAE, continue to engage wide audiences with shared stories from HAEA community members and educational content.
- In 2024, HAEA Health Team Advocates successfully recruited community members for 7 clinical trials that offer promise for additional HAE treatment options.
- During the 2024 hae day :-) campaign, thousands of HAEA friends posted photos with an hae day :-) poster that included personalized messages about their hopes for protecting future generations.
- Since its launch, the HAEA Community Blog has shared 30 articles, reaching over 50,000 readers and fostering a sense of connection and support within the HAE community.
- This summer, the US HAEA gathered a large group of HAEA Youth Interns and Youth Leadership Council members for a 2-day leadership training in Washington, D.C. These leaders-in-training learned about social media advocacy, public speaking, and how to share their story while advocating for the HAE community.
- The HAEA Grassroots Advocacy Network – a group of 1,021 volunteer advocates dedicated to supporting people with HAE through active participation in public policy issues – wrote letters and conducted meetings to support legislation related to a variety of issues that affect people with HAE.
- On July 15th, over 200 HAEA advocates visited 113 congressional offices on Capitol Hill to deliver a vitally important message requesting action on matters that affect the future of people with HAE and their families. You can watch a recap of this event by clicking HERE.
We wish everyone in the HAEi community a joyful and healthy holiday season and a happy, healthy, and productive 2025!
Clinical Trials Update
According to clinicaltrials.gov under the U.S. National Institutes of Health, the EU Clinical Trials Register, and the International Clinical Trials Registry Platform under the World Health Organization (WHO), the following trials are currently or soon to be recruiting (as of 24 November 2024).
Read more about these and other clinical trials at:
HAELO: a Phase 3 Study to Evaluate NTLA-2002 in Participants with Hereditary Angioedema (HAE)
United States
https://clinicaltrials.gov/study/NCT06634420A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
Belgium, Bulgaria, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Puerto Rico, Spain, Turkey, United Kingdom, United States
https://clinicaltrials.gov/study/NCT05392114A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People (SPEAKUP)
No sites confirmed
https://clinicaltrials.gov/study/NCT06587464A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
Poland
https://clinicaltrials.gov/study/NCT05147181C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
Bulgaria, Croatia, Czechia, France, Germany, Hungary, Italy, North Macedonia, Norway, Poland, Slovakia, Slovenia, Sweden
https://www.clinicaltrials.gov/study/NCT01397864A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
United Kingdom
https://clinicaltrials.gov/study/NCT05469789A Survey of Lanadelumab in Participants With Hereditary Angioedema
Japan
https://clinicaltrials.gov/study/NCT05397431A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema
Japan
https://clinicaltrials.gov/study/NCT05509569A Study of STAR-0215 in Participants With Hereditary Angioedema
Bulgaria, Canada, Czechia, Germany, United Kingdom, United States
https://clinicaltrials.gov/study/NCT05695248A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
United States, Canada
https://www.clinicaltrials.gov/study/NCT06007677PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Australia, Austria, Bulgaria, France, Germany, Greece, Israel, Japan, Netherlands, New Zealand, Spain, United Kingdom, United States
https://clinicaltrials.gov/study/NCT05511922CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
Israel, United States
https://clinicaltrials.gov/study/NCT05819775An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Australia, Austria, Bulgaria, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, North Macedonia, Poland, Portugal, Slovakia, South Africa, Spain, United Kingdom, United States
https://clinicaltrials.gov/study/NCT05505916Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Poland, Spain, United States
https://clinicaltrials.gov/study/NCT05396105Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults with Hereditary Angioedema (RAPIDe-3)
United States, Puerto Rico
https://www.clinicaltrials.gov/study/NCT06343779Status of Dental Care Practices in Patients With Hereditary Angioedema
France
https://clinicaltrials.gov/study/NCT05776784Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C-1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
United States, Armenia, Bulgaria, Mexico, Peru, Romania, Serbia, Ukraine
https://www.clinicaltrials.gov/study/NCT06361537Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients
Australia
https://clinicaltrials.gov/study/NCT05691361Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002
France, New Zealand, United Kingdom
https://www.clinicaltrials.gov/study/NCT06262399A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr) in Persons With HAE in China
China
https://clinicaltrials.gov/study/NCT06346899Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) with HAE Type I or II (KONFIDENT-KID)
United States
https://clinicaltrials.gov/study/NCT06467084Institutional Registry of Rare Diseases
Argentina
https://www.clinicaltrials.gov/study/NCT06573723Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE (CHAPTER-3)
No location data
https://www.clinicaltrials.gov/study/NCT06669754Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults with HAE (CHAPTER-4)
No location data
https://www.clinicaltrials.gov/study/NCT06679881Angioedema Biomarker Research Study
No location data
https://www.clinicaltrials.gov/study/NCT06210698Identification and Characterization of Genetic Variants in Hereditary Angioedema (GENOMAEH_01)
HAE-Related Scientific Publications
In addition to a wide range of case reports and small series, here are summaries of recently published HAE-related scientific papers. Data search undertaken 24 November 2024.
CRISPR-based therapy for hereditary angioedema
Danny M Cohn, et al
The authors report the results of a clinical trial of a prospective gene therapy for HAE. The authors state that a single dose of the medicine, code-named NTLA-2002, may provide lifelong control of angioedema attacks. Following the small-scale study, the authors conclude that the therapy reduced angioedema attacks and led to sustained reductions in the kallikrein levels in patients with HAE. They recommend that a larger trial be conducted.
(New England Journal of Medicine, 24 October 2024)
Hereditary angioedema (HAE) in children and adolescents: New treatment options
Maria Fasshauer and Bettina Wedi
The authors review the current treatment options for HAE type I and type II in children and adolescents. They also discuss developments and future therapeutic options.
(Allergologie select, 30 October 2024)
Unveiling the complexities of hereditary angioedema
Cristina Violeta Tutunaru, et al
The authors review the intricacies and diverse presentations of HAE, and the emerging biomarkers and innovations in the management and prevention of HAE.
(Biomolecules, 14 October 2024)
Dietary and physical trigger factors in hereditary angioedema: Self-conducted investigation and literature overview
Julia Zarnowski and Regina Treudler
The authors aimed to investigate the influence of nutrition and physical activity in people with HAE at a Leipzig ACARE center. Thirty patients completed a questionnaire about their life and lifestyle, which, the authors conclude, indicated that dietary factors and physical activity frequently led to an aggravation of HAE. The authors believe patients should be counseled about this when discussing trigger avoidance.
(Allergologie select, 14 November 2024)
Hereditary angioedema and venous thromboembolism: Where there’s smoke, there’s fire
Stephen P Grover
The author highlights and reviews recent epidemiological evidence linking HAE with a significantly increased risk of blood clots in veins (venous thromboembolism or VTE). The review also discusses the impact of HAE-specific medicines on VTE and blood clotting.
(Seminars in Thrombosis and Hemostasis, 17 October 2024)
Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches
Giulia Costanzo, et al
The authors review currently approved drugs for HAE and how treatments are developed. The authors conclude that the availability of newer therapeutic options has led to more individualized treatment plans for patients. The opportunity to switch from one treatment to another has also become easier. The authors foresee attack-free remission becoming a future possibility.
(Current Opinion in Allergy and Clinical Immunology, December 2024)
Structural basis for the inhibition of βFXIIa by garadacimab
Ieva Drulyte, et al
The authors examine both activated factor XII (FXIIa) and garadacimab using an electron microscope, to better understand how they interact and how the chemical structure of both can provide crucial insights into the mechanism of action of this HAE treatment.
(Structure, 3 October 2024)
A clinical evaluation of patients with known mutations (plasminogen and factor XII) with a focus on prophylactic treatment
Robin Lochbaum, et al
The authors analyzed eighteen patients with HAE with normal C1, treated at a clinic in southern Germany. The authors were keen to understand current treatment strategies for these patients, along with disease impact and laboratory values. The authors conclude that all patients received icatibant for on-demand treatment. Additionally, three more patients were given prophylaxis with lanadelumab. In these patients, symptoms and clinical course showed significant improvements.
(Journal of Dermatological Treatment, December 2024)
Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study
Avener Reshef, et al
The authors conducted a clinical trial to investigate the long-term safety and efficacy of garadacimab for HAE prophylaxis. Each patient received treatment for an average of 13.8 months. During this time, 13% of patients reported a side effect from treatment. There were no deaths, and the majority of side effects were mild to moderate. There were three serious side effects reported, but these were not related to garadacimab. The mean HAE attack rate decreased by 95%, and 60% of patients were attack-free. The authors conclude that garadacimab has a favorable safety profile suitable for long-term use and provides long-term protection against HAE attacks.
(Allergy, 7 October 2024)
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema
Dan Sexton, et al
Using computer modeling, the authors developed a virtual patient population to understand the implications of reduced doses of lanadelumab, such as in patients not taking a daily oral dose. The authors conclude that the number of missed doses per month was connected with reduced drug effectiveness. They believe that their model has value in predicting outcomes.
(Journal of Pharmacokinetics and Pharmacodynamics, December 2024)
Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)
Matthew H Rim, et al
The authors review a range of new and forthcoming medications for diseases, including HAE. The authors highlight a potential new oral medication for HAE, as part of supporting pharmacists in their role of horizon scanning for future treatments that will need mnaging in formularies and clinical programs.
(American Journal of Health-System Pharmacy, November 2024)
Hereditary angioedema attacks in patients receiving long-term prophylaxis: A systematic review
Hilary J Longhurst, et al
The authors aim to understand what proportion of HAE patients continue to suffer attacks, despite being on long-term prophylaxis. The authors conclude that patients receiving LTP did experience attacks in all parts of the body, including the larynx. Most of these attacks were treated with on-demand therapy, and as a result, the authors feel that access to on-demand therapy remains essential for all people with HAE.
(Clinical Reviews in Allergy & Immunology, 7 November 2024)
Validation and correlations of the Angioedema Activity Score (AAS), Angioedema Quality of Life (AE-QoL) questionnaire, and Angioedema Control Test (AECT) in Chinese patients with angioedema
Hugo WF Mak, et al
The authors aimed to validate the Chinese version of several patient-reported outcome tools, as there had been no previous research to prove these were relevant for Chinese people with angioedema. After testing amongst 118 Chinese patients with recurrent angioedema, the authors conclude that these are valid and reliable tools for use with Chinese patients.
(Journal of Allergy and Clinical Immunology Global, November 2024)
Virtual reality in specialized dentistry: Employing virtual reality for the alleviation of pain and anxiety in hereditary angioedema patients
Alessio Rosa, et al
The authors aimed to use virtual reality technology to address dental anxiety, which may arise in people with HAE following an episode after dental treatment. In the research, people with HAE were given a dental examination while participating in a VR experience, including wearing a headset. The authors conclude that VR can be an excellent distraction tool in patients with HAE who present at least one acute attack per year.
(Minerva Dental and Oral Science, 29 October 2024)
Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study
Paola Triggianese, et al
The authors were looking to see the prevalence of rare connective tissue diseases, such as lupus, in people diagnosed with HAE. Examining the data from 855 people with C1 inhibitor deficiency HAE, 2.1% of these people also had a rare connective tissue disease.
(Frontiers in Immunology, 18 October 2024)
Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis
John Anderson, et al
The authors wanted to understand the clinical characteristics, attack history, and quality of life of people with HAE treated with lanadelumab as long-term prophylaxis. In conclusion, the authors write that their findings show that there is a lower attack frequency, lower symptomatic impact, and better quality of life in patients treated with lanadelumab than another prophylaxis in a real-world setting.
(Allergy and Asthma Proceedings, 1 November 2024)
Etiology, recent advances, and clinical trials data for the treatment of angioedema: A review
Mukul Nishad, et al
The authors review recent improvements in knowledge and treatment of various forms of angioedema, including HAE. They conclude that over time outcomes for patients have been greatly improved by a growing understanding of the disease and increasing treatment options.
(Reviews on Recent Clinical Trials, 11 October 2024)
The utility of shared decision making in the management of hereditary angioedema
Rachel Odin, et al
The authors wanted to better understand the patient’s perspective of shared decision making in HAE. They did this by asking 10 US HAE treating physicians, a series of questions following a shared decision making consultation with a patient. The patient was also asked their views and the opinions paired. The authors conclude that shared decisions making is being implemented to determine the best management options for patients with HAE.
(Allergy and Asthma Proceedings, 1 November 2024)
A mechanistic model of in vitro plasma activation to evaluate therapeutic kallikrein-kinin system inhibitors
Alirez Rezvani-Sharif, et al
The authors present a new computer model of the complex biochemical pathway that can go wrong and lead to HAE. The authors feel that their model represents a valuable way to study the interactions within the kallikrein-kinin system, to better understand the ways in which HAE treatments that target this system work.
(PLOS Computational Biology, 4 November 2024)
Initial experience of long-term prophylaxis with lanadelumab for hereditary angioedema in China: A clinical observation study on six patients
Wo Yao, et al
The authors investigated the clinical efficacy and safety of lanadelumab for long-term prophylaxis (LTP) in Chinese people with HAE. The authors followed six Chinese patients treated with lanadelumab, finding that LTP with the medication led to a reduction of 97.8% in attack rate, with no serious or severe treatment-emergent adverse events. The authors conclude that this is the first report to demonstrate the clinical efficacy of lanadalumab and safety of LTP in HAE patients from the Chinese mainland. They suggest that a reasonable dosage plan of lanadelumab can ensure quick and long-lasting protection against HAE attacks.
(International Archives of Allergy and Immunology, 3 October 2024)
Prolonging the circulatory half-life of C1 esterase inhibitor via albumin fusion
Sangavi Sivananthan, et al
The authors investigated how to extend the time existing C1 inhibitor-based treatments last in the body. Their findings, they conclude, suggest that there is potential for their technique to be investigated further.
(PLOS One, 23 October 2024)
Deciphering the landscape of hereditary angioedema in India: Perspective for Indian dermatologists
Prabal Barman, et al
The authors looked into HAE from the dermatologist’s perspective and provided detail on the availability of first-line treatment options in India. The authors encourage their readership to suspect HAE in any patient presenting with swelling without itchy and raised red welts (urticaria). Complement C4, they suggest, offers a simple and sensitive test for HAE. The authors suggest that first-line treatment options for HAE are now available in India and must be used to avoid mortality and improve quality of life.
(Indian Journal of Dermatology, Venereology and Leprology, November-December 2024)
Quantification of C1 inhibitor activity using a chromogenic automated assay: analytical and clinical performances
Yves Renaudineau, et al
Quantifying functional C1 inhibitor activity (fC1-INH) is an important way to diagnose angioedemas such as HAE. The authors tested the performance of an assay of fC1-INH. They conclude that the automated assay tested showed good performance, and could be used both for research and in determining quantitative C1-INH and C4.
(Clinical Chemistry and Laboratory Medicine, 26 November 2024)
Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians
Adil Adatia and Markus Magerl
The authors provide a practical guide for clinicians seeking to use berotralstat in patients with HAE. They conclude that berotralstat is an effective treatment and provides patients with an oral long-term prophylaxis option. Stomach and digestive side effects occur in a minority of patients and can be minimized through the gradual introduction of the medication. Berotralstat may interact with other medications. The authors suggest that an overlap period could prevent breakthrough attacks when switching an HAE patient from plasma-derived C1 inhibitor treatment to berotralstat.
(Frontiers in Immunology, 8 October 2024)
The international HAE guideline under real-life conditions: From possibilities to limits in daily life – current real-world data of 8 German angioedema centers
Jens Greve, et al
The authors aim to exchange knowledge between centers to better address the daily care of people living with HAE. The authors conclude that the current HAE guideline serves as the foundation for how HAE should be treated at specialized centers. However, for rare conditions such as HAE, exchanging information between treating centers can address issues that arise.
(Allergologie Select, 14 November 2024)
News from the Industry
BioCryst provides business update
4 November, 2024
BioCryst Pharmaceuticals provided a corporate update.
Jon Stonehouse, President and Chief Executive Officer of BioCryst, said: “Our third quarter performance continues to build on the outstanding year we are having. As we look ahead, we see new opportunities for younger children to benefit from Orladeyo.”
Charlie Gayer, Chief Commercial Officer of BioCryst, said: “The real-world efficacy and convenience patients and physicians are experiencing with Orladeyo are driving accelerated momentum.”
(Source: BioCryst)
Intellia highlights recent company progress
7 November, 2024
Intellia Therapeutics reported operational highlights and financial results for the third quarter ended September 30, 2024.
John Leonard MD, Intellia President and Chief Executive Officer, said: “Our third quarter and recent period have been marked by outstanding progress in advancing our pipeline of CRISPR-based gene editing therapies. A key achievement was the initiation of the HAELO Phase 3 study, which we believe will demonstrate what we’ve seen in the first-in-human study — a one-time treatment of NTLA-2002 has the potential to be a functional cure for hereditary angioedema.”(Source: Intellia)
Pharvaris highlights recent business updates
13 November, 2024
Pharvaris highlighted recent business updates.
Berndt Modig, Chief Executive Officer of Pharvaris, said: “Enrollment in our pivotal Phase 3 on-demand study, RAPIDe-3, progresses as planned, and we are preparing for the initiation of our pivotal Phase 3 prophylaxis study, CHAPTER-3, by year-end.
“Our recently presented positive long-term extension data from our CHAPTER-1 and RAPIDe-2 Phase 2 studies reinforces deucrictibant’s differentiated profile. Together with the data from our randomized clinical trials, we believe deucrictibant’s injectable-like efficacy, placebo-like tolerability, and oral convenience uniquely position it to address unmet need in both the prophylactic and on-demand HAE treatment settings. Our team is now focused on the successful execution of our Phase 3 HAE clinical studies.”
(Source: Pharvaris)
BioCryst launches Orladeyo (berotralstat) in Ireland
18 November, 2024
BioCryst Pharmaceuticals announced that the Health Services Executive (HSE) in Ireland has recommended Orladeyo (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks.
Charlie Gayer, Chief Commercial Officer of BioCryst, said: “The positive HSE recommendation of Orladeyo broadens access to modern prophylaxis, providing greater choice for prescribing physicians and potentially a better quality of life for HAE patients in Ireland.”
The HSE decision in Ireland follows the European Commission marketing authorization of Orladeyo in April 2021. To date, Orladeyo is licensed in 44 countries.
(Source: BioCryst)
Astria announces positive final results from target enrollment in the ALPHA-STAR Phase 1b/2 trial of navenibart for HAE
11 December, 2024
Astria Therapeutics announces positive final results from target enrollment in the ALPHA-STAR Phase 1b/2 trial of navenibart for HAE
Astra Therapeutics announced positive final results from the target enrollment group of 16 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. These final results demonstrated reduction in the mean monthly attack rate of 90-95% at 6 months, favorable safety and tolerability profile, and support both every three- (Q3M) and every six-month (Q6M) dosing regimens. Astria is advancing navenibart to Phase 3 development with trial initiation expected in Q1 2025.
Christopher Morabito MD, Chief Medical Officer at Astria Therapeutics, said: “The results from the ALPHA-STAR Phase 1b/2 trial affirm our belief in navenibart’s profile and its potential to be a life-changing preventative treatment for HAE patients. After one or two doses over six months, patients experienced rapid onset of robust and durable efficacy, favorable safety and tolerability, and PK and PD that are consistent with sustained plasma kallikrein inhibition and Q3M and Q6M administration. These results are highly consistent with the interim results we reported in March. We look forward to presenting these data at an upcoming scientific conference and expect to initiate Phase 3 development in Q1, pending completion of discussions with global regulators.”
Dr Aleena Banerji, Clinical Director, MGH Allergy and Clinical Immunology Unit, said: “These results from the ALPHA-STAR trial are exciting for the future of the HAE treatment landscape. We understand from people living with HAE that the disease and treatment burden can weigh heavily on their physical and mental health. I am optimistic that a therapy with infrequent dosing, a well-tolerated profile, and a trusted mechanism and modality could alleviate the burden for patients.”
(Source: Astria)
KalVista Appoints Jeb Ledell as Chief Operating Officer
18 December, 2024
KalVista Appoints Jeb Ledell as Chief Operating Officer
KalVista Pharmaceuticals announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO).
Ben Palleiko, Chief Executive Officer of KalVista, said: “I am pleased to welcome Jeb to KalVista at this key time in our evolution. His extensive experience in leading teams and driving efficiency within companies like ours makes him a valued addition to the team as we continue to evolve into a commercial entity. I am confident that his proven skills will help us to achieve our goal of delivering sebetralstat to help transform the lives of people living with hereditary angioedema.”
Jeb Ledell, said: “I am excited to join the talented team at KalVista as the Company prepares to launch sebetralstat on a global scale. I am eager to contribute my insights and experience to drive forward the Company’s mission of delivering a transformative new therapy for those impacted by hereditary angioedema.”
(Source: KalVista)
CSL Receives Positive CHMP Opinion for Garadacimab in HAE
18 December, 2024
CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)
CSL announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorization for garadacimab as a once-monthly prophylactic treatment for hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. Garadacimab is a monoclonal antibody that targets activated factor XII (factor XIIa), a plasma protein that plays a key role in attacks of swelling in people with HAE, thereby inhibiting the HAE cascade at the top to prevent HAE attacks. The final European Commission (EC) decision is expected in Q1 2025.
Emmanuelle Lecomte-Brisset, Senior Vice President and Head of Global Regulatory Affairs at CSL, said: “CSL has a longstanding and relentless patient-focused approach to developing transformational medicines in areas of unmet need. This CHMP decision brings us closer to offering an innovative treatment to patients living with HAE, which is a debilitating and potentially life-threatening condition. We look forward to making this therapy available to patients in Europe.”
(Source: CSL)
HAEi Around the World
Currently, there are HAE Member Organizations in 101 countries. You will find a great deal of vital information on the HAE representations around the globe at haei.org, and the world map will provide you with contact information for the Member Organizations, ACARE centers, hospitals, physicians, and available medication.
The information on haei.org is updated as soon as HAEi receives fresh data from the national Member Organizations.
Global Perspectives · Issue 4/2024 · December 2024
Magazine Staff: Henrik Balle Boysen, President; Deborah Corcoran, Chief Scientific Officer; Stuart Mayell, Editor in Chief, Global Perspectives; Rikke Sørensen, Manager, Communication, Design, and Graphics
Subscription: If you would like to subscribe to our magazine, please send an email to info@haei.org or register directly at haei.org
PDF version of the magazine is available on our website – click here to see the PDF or earlier editions of Global Perspectives.
*Google Translate powers the translations on the Global Perspectives website. Google Translate is constantly improving but is not perfect. Not all text may be translated accurately, and some text may not be translated at all. HAEi is not responsible for the quality of translations. The translation should not be considered exact and is an approximation of the English language content. HAEi does not accept any liability for any damage or issues that may result from using Google Translate.
Who we are
HAE International is a global non-profit network of member organizations dedicated to raising awareness of hereditary angioedema and improving the lives of people with HAE.
Contact us
HAE International (HAEi)
10560 Main Street, Ste PS40
Fairfax City, VA 22030
United States of America
info@haei.org
Operations
HAE International (HAEi)
Vejlevej 16, 1.
8700 Horsens
Denmark
info@haei.org